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Fig. S1.  Effects of ATR-101 compared with PD129337 on the cholesterol levels, ATP levels, 
caspase 3/7 activities, and cholesterol esterification, at different times in H295R cells. 
A. Quantitation of the time-dependence of the change in cholesterol levels in H295R cells after 
ATR-101 addition. H295R cells were cultured with DMSO vehicle (-) or with 60 M ATR-101 
(+) for the indicated times. The cells were fixed and stained with filipin III.  Filipin III 
fluorescence was visualized by fluorescence microscopy using a 4X objective. The mean 
fluorescence intensities and areas of 220 to 310 individual H295R cell clusters (approximately 
5500-7800 cells) for each time and condition were quantified using ImageJ v1.50i software.  To 
quantify the areas and intensities of the clusters, manual fluorescence intensity thresholding was 
used to divide each image into signal comprising the cell clusters and background.  The 
intensity divided by the area was plotted for each cell cluster.  The mean, quartiles and ±2SD 
were plotted at each time after ATR-101 addition. The statistical significance of the differences 
in fluorescence intensity after ATR-101 addition were evaluated by using unpaired two-tailed 
Student’s t-tests  (Cells cultured with ATR-101 versus corresponding control cells; *P < 0.05). 
The data are representative of two experiments.   
           ATR-101 caused an increase in cholesterol accumulation within 15 minutes after 
addition to H295R cells.  There was a wide range of filipin III intensities among different cell 
clusters, but the majority of cell clusters had a narrower range of intensities as indicated by the 
quartiles shown. 
B. Effects of different concentrations of ATR-101 versus PD129337 on the ATP levels and on 
the caspase 3/7 activities in H295R (upper graphs) and BD140C (lower graphs) cells.  The cells 
were cultured with the indicated concentrations of ATR-101 (closed triangles) or PD129337 
(open squares) for 24 h.   The ATP levels (left graphs) and the caspase 3/7 activities (right 
graphs) were measured in cells that were cultured in parallel.  The graphs show the means and 
the standard deviations of six samples from three experiments.  The statistical significance of 
the differences in ATP levels and caspase 3/7 activities in cells that were cultured with each 
concentration of ATR-101 or PD129337 were evaluated by using two-way analysis of variance 
followed by Sidak’s post hoc tests (ATR-101 vs. PD129337, *P < 0.05). 
ATR-101 reduced the ATP levels and increased the caspase 3/7 activities in H295R and 
BD140C cells.  The concentrations of ATR-101 that were required for ATP depletion and for 
caspase 3/7 activation were similar in each of the cells lines, but they were slightly different 
between H295R and BD140C cells.  PD129337 had no detectable effect on the ATP levels or 
the caspase 3/7 activities in these cells.  ACAT inhibition was therefore not sufficient to cause 
ATP depletion or caspase 3/7 activation in these cells. 
C. Effects of different concentrations of ATR-101 versus PD129337 on NBD-cholesterol 
esterification in H295R cells.  The cells were incubated with the indicated concentrations of 
ATR-101 or PD129337 for 2 h, followed by 2 h with added NBD-cholesterol (1 g/ml).  The 
images show NBD (green) and Hoechst (blue) fluorescence captured with a 20X objective and 
are representative of two independent experiments.  The concentrations of ATR-101 and 
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PD129337 that inhibited cholesterol esterification in H295R and BD140C cells were similar to 
the concentrations that inhibit ACAT enzyme activity in vitro (Trivedi et al., 1993; Trivedi et 
al., 1994). The scale bars denote 30 m.   
           We compared the effects of ATR-101 and of PD129337 on cholesterol esterification in 
ACC-derived cells by imaging NBD-cholesterol accumulation in lipid droplets. PD129337 
inhibited NBD-cholesterol accumulation more effectively than ATR-101.  The inhibition of 
NBD-cholesterol esterification by low concentrations of ATR-101 and by PD129337 does not 
correlate with cholesterol accumulation or with ATP depletion or caspase 3/7 activation in 
H295R cells.  The inhibition of cholesterol esterification as well as other effects of PD129337 in 
H295R cells (Fig. S7A) indicate that PD129337 accessed the same locations as ATR-101 in 
cells. 
D. The entire fields from which the images in Figure 1C were cropped are shown for H295R 
(upper images) and for BD140C (lower images) cells.  H295R and BD140C cells were cultured 
with DMSO vehicle or with the indicated concentrations of ATR-101 or of PD129337 for 4 h.  
After 4 h, the media was removed from the cells and immediately replaced with 4% 
paraformaldehyde and fixed at room temperature for 20 min.  Cells were washed twice in PBS.  
Prior to staining, a stock solution of filipin III was prepared in DMSO (10 mg/ml).  The filipin 
III stock solution was diluted 100X in PBS for a final concentration of 100 g/ml and added 
directly to cells.  Cells were incubated with filipin III at 37C in the dark for 2 h, washed twice in 
PBS.  Filipin III fluorescence was visualized by confocal fluorescence microscopy using an 
excitation wavelength of 387/11 nm with a 60X oil objective.  The images show filipin III 
fluorescence and are representative of two independent experiments for each cell line.   The 
scale bars denotes 10 m. 
 ATR-101 caused an increase in cholesterol accumulation in the plasma membrane.  The 
filipin III staining intensities of individual cells in a cluster varied, and the overall filipin III 
staining intensities of H295R cells that were cultured with ATR-101 were significantly different 
from control cells and cells that were cultured with PD129337. 
E. The entire fields from which the images in Figure 1E were cropped are shown.  H295R cells 
were incubated with 1 M of ATR-101 or PD129337 for 2 h, followed by 1.5 h with added 
NBD-cholesterol (1 g/ml).  After 1.5 h, Hoechst 33342 was added at a final concentration of 3 
g/ml.  After 30 min, the media was removed and replaced with fresh media.  The cells were 
visualized using confocal fluorescence microscopy using excitation wavelengths of either 
485/20 nm (NBD) or 387/11 nm (Hoechst) with a 20X objective.  The images show NBD 
(green) and Hoechst (blue) fluorescence and are representative of images collected in five 
independent experiments for each cell line.   The scale bars denote 30 m.  
 NBD-cholesterol produced a variable number of foci with intense fluorescence and a 
diffuse fluorescence of variable intensity in control H295R cells.  ATR-101 and PD129337 at 
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Figure S2. Effects of ATR-101 in combination with MCD or with exogenous cholesterol on the 
cholesterol levels, ATP levels, caspase 3/7 activities, and cholesterol crystallization. 
A.  Effects of ATR-101 in combination with MCD or with exogenous cholesterol on the 
cholesterol levels of H295R cells.  The cells were cultured with DMSO vehicle (left images) or 
with 40 M ATR101 (right images) alone (top row), together with 2 M MCD (second row), 
160 M cholesterol (third row), or 160 M cholesterol linoleate (fourth row) for 24 h.  MCD 
is a cholesterol-binding compound that removes unesterified cholesterol from cell membranes 
(Yu et al., 2005; Le Goff et al., 2006) (Mahammad and Parmryd, 2008). Cholesterol was 
visualized using filipin III.  The images show filipin III fluorescence (upper set of images) and 
phase contrast (lower set of images), and are representative of two independent experiments. 
The scale bars denote 30 m. 
           ATR-101 caused an increase in intracellular cholesterol and in cholesterol crystallization 
at the plasma membrane.  MCD blocked the effects of ATR-101 on cholesterol accumulation 
and on cholesterol crystallization at the plasma membrane.    The cholesterol crystals were not 
visualized by filipin III, suggesting that the crystalline cholesterol is either inaccessible to filipin 
III binding, or is dislodged during the staining procedure.  Exogenous cholesterol linoleate did 
not prevent the accumulation of cellular cholesterol in response to ATR-101. 
B. Effects of MCD on ATP depletion and caspase 3/7 activation by ATR-101 in H295R cells.  
The cells were cultured with the indicated concentrations of MCD together with DMSO 
vehicle or 50 M ATR-101 for 24 h.  The ATP levels (left graph) and the caspase 3/7 activities 
(right graph) we measured in cells that were grown in parallel.  The graphs show the means and 
the standard deviations of six samples from three experiments.  The statistical significance of 
the differences in ATP levels and caspase 3/7 activities  in cells that were cultured with each 
concentration of MCD were evaluated by using one-way analysis of variance followed by 
Dunnett’s post hoc tests (cells cultured with MCD vs. corresponding controls, *P < 0.05).   
MCD suppressed the depletion of ATP and caspase 3/7 activation by ATR-101 in a 
concentration-dependent manner after 4 h. 
 
C.  Effects of exogenous cholesterol on ATP depletion and the caspase 3/7 activation by ATR-
101 in H295R cells.  The cells were incubated with DMSO or with 50 M ATR-101 together 
with the indicated concentrations of exogenous cholesterol for 4 h.  The ATP levels (left graph) 
and the caspase 3/7 activities (right graph) we measured in cells that were grown in parallel.  
The graphs show the means and the standard deviations of six samples from three experiments.  
The statistical significance of the differences in ATP levels and caspase 3/7 activities in cells 
that were cultured with each concentration of exogenous cholesterol were evaluated by using 
one-way analysis of variance followed by Dunnett’s post hoc tests ( cells cultured with 
exogenous cholesterol vs. vs. corresponding controls, *P < 0.05).   
Exogenous cholesterol reduced ATP depletion, but did not affect caspase 3/7 activation 
by ATR-101 after 4 h.  The differential effects of exogenous cholesterol on ATP depletion versus 
14 
 
caspase 3/7 activation by ATR-101 demonstrate that ATP depletion and caspase 3/7 activation 
by ATR-101 are independent.  
 
D. Comparison of the effects of exogenous cholesterol and exogenous cholesterol linoleate on 
ATP depletion by ATR-101.  H295R cells were cultured with DMSO or with 40 M ATR-
together with the indicated concentrations of exogenous cholesterol or exogenous cholesterol 
linoleate for 24 h and the ATP levels were measured.  The graphs show the means and the 
standard deviations of two samples from one experiment and are representative of two 
experiments.  The statistical significance of the difference in ATP levels in cells that were 
cultured with ATR-101 and cholesterol or ATR-101 and cholesterol linoleate was evaluated by 
using unpaired two-tailed Student’s t-test  (n=6, *P < 0.05).  The ATP levels that are shown in 
Fig. S2D were measured in parallel with the visualization of cholesterol by filipin III binding in 
Fig. S2A.   
Exogenous cholesterol but not exogenous cholesterol linoleate inhibits ATP depletion by 
ATR-101 after 24 h.  The distinct effects of the exogenous cholesterol versus the cholesterol 
linoleate as well as the accumulated cellular cholesterol indicate that the exogenous cholesterol 
suppressed ATR-101 cytotoxicity by acting through a mechanism or at a location that was not 
accessible to the cholesterol that was generated inside cells that were cultured with ATR-101.  
  
E.  Visualization of the effects of ATR-101 alone and in combination with MCD or with 
exogenous cholesterol on cell morphology after 30 h.  The cells were cultured with DMSO 
vehicle (upper images) or with 40 M ATR-101 (lower images) alone (left images), or in 
combination with 1.5 mM MCD (middle images), or in combination with 40 M cholesterol 
(right images).   Cell morphology was visualized by phase contrast microscopy using a 10X 
objective. The images are representative of 5 fields under each set of culture conditions.  The 
scale bars denote 100 m. 
              H295R cells incubated with ATR-101 were small, rounded and weakly attached to the 
plate after 30 h.   These changes in morphology are consistent with the loss of cell viability. The 
effects of ATR-101 on cell morphology were prevented in cells that were cultured with ATR-
101 in combination with either MCD or cholesterol. 
F. Effect of ATR-101 on resazurin reducing potential in H295R cells.   The cells were cultured 
with DMSO vehicle or with 32 M ATR-101 alone, or together with 2 mM MCD.  Resazurin 
fluorescence intensity was measured using a microplate reader at the indicated times at 37 C.  
The background signal of wells without resazurin was subtracted.  The graph shows the means 
and the standard deviations of six samples from three experiments.  The statistical significance 
of the differences in resazurin reducing potential at each time after ATR-101 addition in either 
the absence or the presence of MCD were evaluated by using two-way analysis of variance 
followed by Sidak’s post hoc tests (ATR-101 vs. DMSO control, *P < 0.05).  
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 ATR-101 caused a sustained increase in resazurin fluorescence 1 h after addition to the 
culture medium.  The increase in resazurin fluorescence caused by ATR-101 was not inhibited 
by MCD, indicating that it was independent of cholesterol accumulation or ATP depletion by 
ATR-101. 
 
G. Effects of ATR-101 in combination with exogenous cholesterol on NBD-cholesterol 
esterification and on extracellular cholesterol crystal formation in H295R cells.  H295R cells 
were incubated with DMSO or with 100 M ATR-101 alone or together with 40 M of 
exogenous cholesterol for 2 h, followed by 2 h with added NBD-cholesterol (1 g/ml).  The 
images show NBD (green) fluorescence (left images) and phase contrast (right images) captured 
with a 60X objective.  The scale bars denote 30 m. 
ATR-101 inhibits NBD-cholesterol esterification in the absence and in the presence of 
exogenous cholesterol.  This indicates that exogenous cholesterol did not prevent ATR-101 
entry into cells, or the inhibition of cholesterol esterification by ATR-101. 
Exogenous cholesterol in combination with ATR-101 increased the amount of 
extracellular cholesterol crystals and prevented intracellular cholesterol accumulation.  
Abundant crystals were observed at cells that were cultured with ATR-101 together with 
exogenous cholesterol for 4 h, whereas cholesterol crystals were not visible at cells that were 
cultured with ATR-101 or exogenous cholesterol separately for 4 h.  We hypothesize that the 
exogenous cholesterol nucleates cholesterol crystallization at the plasma membrane.  The 
increase in cholesterol crystallization at cells that were cultures with ATR-101 and exogenous 
cholesterol was corroborated by measurement of the amount of cell-associated cholesterol that 
was associated with the cells (Fig. 2F).  The amount of cholesterol that was released into the 
wash medium during the 30 second wash is a minimum estimate of the extracellular cholesterol 
that was associated with the cells since a larger amount of cholesterol was released during a 
longer incubation with the wash medium.  It is unlikely that the extracellular cholesterol was 
released by cell lysis since cells that were cultured with ATR-101 together with exogenous 
cholesterol had a higher ATP level and a lower caspase 3/7 activity than cells that were cultures 
with ATR-101 alone.  This indicates that the protection from ATR-101 cytotoxicity by 
exogenous cholesterol correlates with cholesterol crystal formation and an increase in the 
amount of extracellular cholesterol that is associated with the cells. 
 
H.  Effects of cholesterol:MCD on the cholesterol levels of H295R cells.  The cells were 
cultured with the indicated concentrations of cholesterol:MCD for 4 h.  The images show 
filipin III fluorescence and are representative of images from two separate experiments.  The 
scale bars denote 10 m.  
We investigated the effects of cholesterol accumulation independently of ATR-101 by 
culturing H295R cells in the presence of cholesterol:MCD.  Cholesterol:MCD concentrations 
that were 10-100 fold higher than the concentrations of exogenous cholesterol increased the 
intracellular cholesterol levels of H295R cells.  At moderate cholesterol:MCD concentrations 
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(0.6 mM), the cholesterol was localized mainly to intracellular foci, and at the highest 
cholesterol:MCD concentrations (1.2 mM), the cholesterol accumulated mainly in the plasma 
membrane.  We were unable to visualize the cholesterol in cells that were cultured with 
cholesterol:MCD in combination with ATR-101 since the cells that were cultured under these 
conditions did not adhere to slides under the conditions that are required to visualize filipin III 
binding. 
 
I.  Effects of ATR-101 in combination with cholesterol:MCD on the ATP levels and the 
caspase 3/7 activities of H295R cells.  The cells were cultured with the indicated concentrations 
of cholesterol:MCD together with DMSO vehicle or 50 M ATR-101 for 4 h (upper graphs) or 
24 h (lower graphs), followed by measurement of the ATP levels (left graph) and caspase 3/7 
activities (right graph).  The graphs show the means and the standard deviations of six samples 
from three experiments.  The statistical significance of the differences in ATP levels and caspase 
3/7 activities in cells that were cultured with each concentration of cholesterol:MCD were 
evaluated by using two-way analysis of variance followed by Dunnett’s post hoc tests (cells 
cultured with cholesterol:MCD  vs. corresponding controls, *P < 0.05) 
           Moderate cholesterol:MCD concentrations (≤0.5 mM) reduced ATP depletion by ATR-
101 at 4 h and 24 h after addition to H295R cells, consistent with the reduction in ATR-101 
dependent ATP depletion by exogenous cholesterol (Fig. 2C).  The highest cholesterol:MCD 
concentrations (≥1 mM) reduced ATP depletion by ATR-101 after 4 h, but they caused ATP 
depletion both alone and in combination with ATR-101 after 24 h.  Cholesterol:MCD 
increased the caspase 3/7 activity both alone and in combination with ATR-101 both at 4 h and 
at 24 h after addition to H295R cells.  Cholesterol:MCD therefore had effects in combination 
with ATR-101 that were distinct from the effects of MCD and of exogenous cholesterol 
separately.  The differences between these effects are likely to be due to the distinct activities of 
the low concentrations of exogenous cholesterol alone and the high concentrations of 
cholesterol complexed with MCD 
J.    The full fields from which the images in Fig. 2A (white rectangles) were taken.  The scale 
bars denote 30 m.  H295R cells that were cultured with ATR-101 have higher levels of filipin 
III binding to the plasma membrane than control cells.  Cells that were cultured with ATR-101 
together with MCD did not have a higher level of filipin III binding to the plasma membrane.   
 
K.  The full fields from which the images shown in Fig. 2C (white rectangles) were taken.  The 
scale bars denote 30 m. H295R cells that were cultured with ATR-101 have higher levels of 
filipin III binding to the plasma membrane than control cells.  Cells that were cultured with 
ATR-101 together with exogenous cholesterol did not have a higher level of filipin III binding 



































































































































Figure S3.  Effects of ATR-101 and of ABC transporter inhibitors on the cholesterol levels of 
H295R cells that were cultured in serum-free medium for 4 h.   
A. Comparison of the effects of glibenclamide, verapamil, and ATR-101 on the cholesterol 
levels in H295R cells that were cultured in serum-free medium.  The medium of cells that were 
cultured under standard conditions was replaced with serum-free media containing apoA-I with 
either DMSO vehicle, 50 M glibenclamide, 50 M verapamil, or 50 M ATR-101 for 4 h.  The 
cholesterol in the cells was visualized by filipin III binding.  The images show filipin III 
fluorescence and are representative of two independent experiments.  The scale bars denote 30 
m. 
 Verapamil and ATR-101 but not glibenclamide increased the level of cholesterol in 
intracellular membranes of H295R cells that were cultured in serum-free medium.  The lack of 
cholesterol accumulation in cells that were cultured with glibenclamide indicates that the 
inhibition of cholesterol efflux was not sufficient to cause cholesterol accumulation in H295R 
cells.   The increase in cholesterol in cells that were cultured with verapamil indicates that the 
inhibition of cholesterol efflux was not necessary for cholesterol accumulation.  The increase in 
cholesterol efflux caused by verapamil under these same conditions is an independent indicator 
of the increase in intracellular cholesterol caused by verapamil (Fig. 3D).  The increase in 
cholesterol efflux caused by verapamil likely represents a compensatory mechanism in response 
to MDR1 inhibition by verapamil.  
  
B.  The full fields from which the images in Fig. 3A (white rectangles) were taken.  The scale 
bars denote 30 m. 
 ATR-101 increased the cholesterol levels in H295R cells that were cultured in serum-
free medium.  MCD suppressed the cholesterol accumulation that was caused by ATR-101 in 
serum-free medium.   MCD also reduced the basal level of cholesterol in H295R cells that 
were cultured in serum-free medium.  
The rate of cholesterol efflux in the absence of ATR-101 corresponded to 5% of the total 
amount of cholesterol and cholesterol esters per hour in H295R cells.  The inhibition of 
cholesterol efflux alone was therefore unlikely to account for the accumulation of cholesterol in 
cells that were cultured with ATR-101.  Additional activities of ATR-101 likely contributed to 
cholesterol accumulation and cytotoxicity. 
 
C.  Effects of glucose and -tocopherol on cholesterol efflux versus ATP levels in H295R cells 
cultured with ATR-101.  The levels of cholesterol in the medium (upper graphs) and of cellular 
ATP (lower graphs) were measured in the same cultures 4 h after replacing the standard culture 
medium with serum-free media containing apoA-I and DMSO vehicle (white bars) or 100 M 
ATR-101 (line graphs) and the indicated concentrations of glucose (left) or -tocopherol (right).  
 ATR-101 inhibited cholesterol efflux under conditions in which the ATP levels were 






















































































































Figure S4. Effects of ATR-101 and of MDR1 inhibitors on cortisol secretion and on doxorubicin 
accumulation. 
 
A.  Comparison of the effects of ATR-101 and verapamil on cortisol secretion.  The cells were 
switched to media with DMSO vehicle, 100 M ATR-101, or 100 M verapamil.  The levels of 
cortisol secreted into the media were measured at the indicated times.  The graph shows the 
means and the standard deviations of five samples from two experiments.  The statistical 
significance of the differences in the cortisol concentrations in the medium at each time after 
verapamil addition were evaluated by using two-way analysis of variance followed by Sidak’s 
post hoc tests (verapamil vs. DMSO controls, *P < 0.05).  
 ATR-101 and verapamil inhibited cortisol secretion from H295R cells with similar 
efficiencies.  The inhibition of cortisol secretion by verapamil suggests that MDR1 is required 
for the cortisol secretion that is detected in the ACC-derived cells.   Cortisol secretion from 
H295R cells was increased by forskolin, consistent with the induction of corticosteroid 
biosynthesis by cAMP signaling (Rainey et al., 1993). 
 
B.  Comparison of the effects of zosuquidar, ATR-101, and ATR-101 together with olesoxime 
on cortisol secretion and on the ATP levels of H295R cells.  The cells were switched to media 
containing indicated concentrations of zosuquidar, ATR-101, or ATR-101 together with 40 M 
olesoxime.  The levels of cortisol secreted into the media (upper graph) and the cellular ATP 
levels (bottom graph) were measured after 4 h.  The graphs show the means and the standard 
deviations of five samples from two experiments.   The statistical significance of the differences 
in the cortisol concentrations in the medium and the ATP levels in the cells that were cultured 
with the indicated concentrations of the compounds were evaluated by using one-way analysis 
of variance followed by Dunnett’s post hoc tests (clls cultured with ATR-101 or zosuquidar vs. 
corresponding controls, *P < 0.05).   
 Zosuquidar inhibited cortisol secretion from H295R cells.  Zosuquidar selectively 
inhibits MDR1 and does not inhibit the closely related MRP1, MRP2, or BCRP ABC 
transporters (Shepard et al., 2003) .  An 8-fold higher concentration of of zosuquidar did not 
cause ATP depletion.  MDR1 inhibition was therefore not sufficient for ATP depletion. 
Perturbations to mitochondrial functions can affect steroidogenesis and cholesterol 
efflux (Midzak et al., 2011b; Graham, 2015).  ATR-101 inhibited cholesterol efflux (Fig. 3E) 
and cortisol secretion (Fig. S4B) in the absence and in the presence of the mitoprotective 
compound olesoxime (Bordet et al., 2010) to the same extent.  Olesoxime reduced ATP 
depletion by ATR-101 (Fig. 3E, S4B).  ATR-101 therefore inhibited cholesterol efflux and 
cortisol secretion by mechanisms that did not require full ATP depletion.   
 
C.  Effects of different ABC transporter inhibitors on doxorubicin accumulation in H295R cells.  
The cells were cultured in the presence of 25 M doxorubicin together with DMSO vehicle, 20 
M benzamil, 20 M verapamil, or 20 M ATR-101.  The levels of doxorubicin in the cells 
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were imaged after 2 h by fluorescence microscopy using a 20X objective. The images show 
doxorubicin fluorescence and are representative of images from two independent experiments.  
The scale bars denote 100 m. 
 A low level of doxorubicin fluorescence was detected in H295R cells that were cultured 
with doxorubicin in the absence of MDR1 inhibitors.  ATR-101 and verapamil increased 
doxorubicin accumulation suggesting that they inhibited MDR1 activity.  Benzamil did not 
increase doxorubicin accumulation, consistent with the export of doxorubicin primarily by 
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Figure S5.  Combined effects of ABC transporter inhibitors with each other and with ATR-101 
on the ATP levels of H295R cells. 
 
A.  Effects of different combinations of ABC transporter inhibitors on the ATP level of H295R 
cells.  The cells were cultured with the indicated concentrations of glibenclamide in 
combination with DMSO vehicle or with verapamil (50 M), benzamil (50 M), and PD129337 
(1 M).  The ATP levels of the cells were measured 4 h after addition of the compounds.  The 
data show the means and standard deviations of two cultures of cells with each concentration of 
each combination of inhibitors, and are representative of the results from two experiments.  
Inhibitors of ABCA1, ABCG1 and MDR1 had a synergistic effect on ATP depletion in 
H295R cells.  ATP depletion by these ABC inhibitors was not enhanced by ACAT inhibition. 
 
B.  Effects of ATR-101 in combination with selective ABC transporter inhibitors on H295R 
cells.  H295R cells were cultured with the indicated concentrations of ATR-101 together with 
DMSO vehicle, glibenclamide (100 M or 500 M), benzamil, rhodamine 123, or cyclosporine 
A (20 M each), in the absence and in the presence of 2 mM MCD.  The ATP levels of the 
cells were measured after 4 h.  The graphs show the means and the standard deviations of two 
cultures of cells with each concentration of each combination of inhibitors, and are 
representative of the results from two experiments. The data for the graphs shown with different 
ABC transporter inhibitors were obtained in separate experiments.   
 ATR-101 in combination with ABCG1 (benzamil) and MDR1 (cyclosporin A, 
verapamil) inhibitors caused larger than additive reductions in the ATP levels of cells.  ATR-101 
in combination with an ABCA1 inhibitor (glibenclamide) did not cause a larger than additive 
reduction in the ATP levels of cells.  The combined effects of ATR-101 with selected ABC 
transporter inhibitors on ATP depletion were suppressed by MCD, indicating that the 
combined cytotoxicity required cholesterol accumulation.  ATR-101 in combination with the 
mitochondrial inhibitor and MDR1 substrate rhodamine-123 also caused larger than additive 
reductions in the ATP levels of cells.  These result suggest that the potency of ATR-101 was 
enhanced when it was used in combination with inhibitors of ABCG1, MDR1, or mitochondrial 
functions.   
 
C. Effects of ATR-101 and benzamil on the cholesterol level of H295R cells.  The cells were 
cultured with DMSO vehicle or 20 M ATR-101 and 5 M benzamil, separately and in 
combination for 1 h.  The cells were fixed and the cholesterol was visualized using filipin III.  
The images show filipin III fluorescence captured with a 60X oil objective and are 
representative of two independent experiments. The scale bars denote 30 m.  
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Figure S6.  Effects of ATR-101 in combination with inhibitors of steroidogenesis on the ATP 
levels of H295R cells. 
A. Effects of different inhibitors of steroidogenesis on ATP depletion by ATR-101.   H295R 
cells were cultured with DMSO vehicle or the indicated concentrations of ATR-101 together 
with the indicated concentrations of abiraterone acetate, ketoconazole, anastrozole, trilostane, or 
metyrapone for 4 h and the ATP levels were measured.  The graphs show the means and the 
standard deviations of two cultures of cells with each concentration of each combination of 
inhibitors shown, and are representative of results from two experiments. The data for the 
graphs shown were obtained from parallel cultures with all inhibitors.  
 The diagram on the right shows the principal targets of abiraterone acetate, 
ketoconazole, anastrozole, trilostane, and metyrapone in the major branches of adrenocortical 
steroidogenesis.  The enzymes are indicated inside the rectangles and the rectangles are 
superimposed on the reactions (arrows) that they catalyze.  Only a subset of the intermediates 
are shown.   Pregnenolone (P5); 17-hydroxypregnenolone (17-OHP), 
dihydroepiandrostenedione (DHEA), dihydroepiandrostenedione sulfate (DHEAS), 
progesterone (P4), 17-hydroxyprogesterone (17-OHP4), androstenedione (A4), corticosterone 
(DOC), 11-deoxycortisol (S), estrone (E1), corticosterone (CORT). 
 Low concentrations of many different inhibitors of steroidogenesis reduced ATP 
depletion by ATR-101.  The concentrations of the inhibitors that reduced ATP depletion by 
ATR-101 were consistent with their inhibitory coefficients for different steroidogenic enzymes 
(Takahashi et al., 1990; Johansson et al., 1998; Garrido et al., 2014).  High concentrations of 
some of these inhibitors enhanced ATP depletion both alone and in combinatioin with ATR-
101.  The concentrations of ketoconazole and abiraterone acetate that enhanced ATP depletion 
were consistent with the concentrations that inhibit MDR1 (Siegsmund et al., 1994; Benoist et 
al., 2016).   
Exogenous steroids and synthetic androgen derivatives can influence cholesterol 
trafficking and metabolism (Liscum and Faust, 1989; Butler et al., 1992; Debry et al., 1997; 
Lange et al., 1997; Hartgens et al., 2004; Lucken-Ardjomande et al., 2008; Midzak et al., 
2011a; Garevik et al., 2012; Midzak et al., 2012).   These results suggest that steroid 













































































Figure S7.  Effects of ATR-101 compared with PD129337 on transcript levels in H295R cells. 
A.  Comparison of the effects of ATR-101 and PD129337 on transcription of ABCA1, ABCG1 
and CHOP.  The levels of the transcripts indicated in each graph are plotted in cells that were 
cultured with the concentrations of ATR-101 or PD129337 indicated at the bottom of the figure 
for 4 h.  The transcript levels were normalized by the RPL9 transcript levels.  The graphs show 
the means and the standard deviations of five samples from four experiments.  The statistical 
significance of the differences in transcript levels in cells that were cultured with each 
concentration of ATR-101 or PD129337 were evaluated by one-way analysis of variance 
followed by Dunnett’s post hoc tests (cells cultured with ATR-101 or PD129337 vs. cells 
cultured with DMSO, *P < 0.05).   
 ATR-101 and PD129337 inhibited liver X receptor target genes (ABCA1 and ABCG1) 
and activated the ER-stress response gene (CHOP) within 4 h after drug exposure.  The effects 
of PD129337 on these transcripts levels indicate that they are not a result of cytotoxicity. 
 
B.   Model for ATR-101 binding to LXR.  A web-based docking program (http://swissdock.eu) 
(Grosdidier et al., 2007) was used to simulate ATR-101 binding to LXR (PDB ID: 1UHL).  
The LXR ligand binding pocket is displayed in surface area representation.  ATR-101 is 
displayed in stick representation.  The ATR-101 docking shown is representative of 24 dockings 
inside of the ligand binding pocket out of a total of 256 dockings.   
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Supporting Materials and Methods 
 
Reagents 
ATR101, PD129337 (Sigma #PH001507), glibenclamide (Abcam #ab120267), zosuquidar 
(Sigma #SML1044), benzamil (Sigma #B2417), cyclosporin A (Cayman #12088), rhodamine 
123 (Cayman #16672), olesoxime (ToCris #2906), doxorubicin  (Cayman #15007), 
ketoconazole (Sigma #K1003), abiraterone acetate (Cayman #15148), metyrapone (Cayman 
#14994), trilostane (Cayman #14164), anastrozole (Cayman #11987), and U18666A (Sigma 
#U3633) were dissolved in DMSO at concentrations ranging from 50 to 250 mM.  The final 
concentration of DMSO for all samples within each experiment was the same and ranged from 
0.1 to 0.4% for all experiments.  NBD-cholesterol (Molecular Probes #N1148), cholesterol 
(Sigma #C3045), cholesterol linoleate (Sigma #C0289), and -tocopherol (Sigma #T3251) were 
dissolve in ethanol at concentrations ranging from 20 to 240 mM.  The final concentration of 
ethanol for all samples within each experiment was the same and ranged from 0.02 to 0.2% for 
all experiments.  Verapamil (Sigma #V4629), methyl--cyclodextrin (Sigma #C4555), and 
cholesterol:methyl--cyclodextrin (Sigma #C4951) were dissolved in the cell culture media. 
 
Cell Culture 
The H295R adrenocortical carcinoma cell line was obtained from ATCC.  The cells were tested 
and confirmed to be free of mycoplasma by Radil Inc.  The BD140C adrenocortical carcinoma 
cell line was kindly provided by Dr. Kimberly Bussey (TGen, Pheonix, Arizona).  The cell lines 
were cultured in DMEM/F12 media (Gibco #11330) supplemented with 10% FBS (Atlanta 
Biologicals #S11595, lots E12069, H1030), and 1% penicillin-streptomycin (Gibco #15140).  7-
9 days before each experiment the cells were passed 2 times in DMEM without glucose 
(Gibco#11966) supplemented with 10 mM galactose, 5% FBS (Atlanta Biologicals # S11595, 
lots E12069, H1030), 1% penicillin-streptomycin (Gibco #15140), 1% L-glutamate (Gibco 
#25030), 5 mM sodium HEPES, and 1 mM sodium pyruvate.  The total serum cholesterol 
concentration in the culture medium was 42.7 M.   The cells were allowed to adhere to the 
tissue culture plates for 48 h after the second passage before the start of each experiment.   
 
Visualization of cholesterol in cells 
The cells were seeded in 96-well ibiTreat -Plates (Ibidi #89626) in 100 l at a density of 
50,000 cells per well.  After 48 h, 20-80 l media was removed from each well and replaced 
with 20 l of each compound diluted to 6X of the final concentration in the culture medium to 
produce a final volume of 120 l.  The cells were incubated at 37 C in 5% CO2 atmosphere for 
a time ranging from 15 min to 24 h.  The medium was removed and immediately replaced with 
100 l of 4% paraformaldehyde and the cells were fixed at room temperature for 20 min.  The 
cells were washed twice with 200 l PBS.  The freshly prepared filipin III (Cayman #70440) 
stock solution (10 mg/ml in DMSO) was diluted 100X in PBS for a final concentration of 100 
g/ml and added directly to cells.  The fixed cells were incubated with filipin III at 37C in the 
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dark for 2 h.  The cells were washed twice with 100 l PBS, and the bound filipin III was 
visualized by fluorescence microscopy using 377±11 nm excitation and 447±60 nm emission 
wavelengths with a 60X oil objective. 
 
Visualization of cholesterol esterification in cells 
The cells were seeded in 96-well ibiTreat -Plates (Ibidi #89626) in 100 l at a density of 
50,000 cells per well.  After 48 h, 20-80 l media was removed from each well and replaced 
with 20 l of each compound diluted to 6X of the final concentration in the culture medium to 
produce a final volume of 120 l.  The cells were incubated at 37 C in 5% CO2 atmosphere for 
either 2 or 22 h.  5 l of NBD-cholesterol was added to each well to produce a final 
concentration of 1 M.  When NBD-cholesterol is esterified and localized to cytoplasmic lipid 
droplets, it produces bright fluorescent foci in the cell.  The inhibition of ACAT activity 
prevents fluorescent focus formation by NBD-cholesterol (Lada et al., 2004).  After 1.5 h, 5 l 
of Hoechst 33342 was added to each well to produce a final concentration of 3 g/ml.  After 30 
min, the medium was replaced with fresh medium.  NBD-cholesterol esterification was 
visualized by fluorescence microscopy using either 485/20 nm (NBD) or 387/11 nm (Hoechst) 
excitation wavelengths and images were captured using either a 60X oil objective or a 20X 
objective. 
  
Cellular ATP level 
The cells were seeded in 96-well tissue culture plates (Corning #3585) in 100 l  at a density of 
25,000 cells per well.  After 48 h, 20-80 l of medium was removed from each well and 
replaced with 20 l of each compound diluted to 6X of the final concentration in the culture 
medium to produce a final volume of 120 l.  The cells were incubated at 37 C in 5% CO2 
atmosphere for a time ranging from 15 min to 24 h.  The medium was removed and 
immediately replaced with 50 l of CellTiter-Glo luminescence cell viability assay reagent 
diluted in buffer according to the manufacturer’s protocol (Promega #G7572). The cells were 
lysed by agitation at room temperature for 20 min in the dark.  The luminescence was measured 
using a SpectraMax M5 microplate reader (Molecular Devices) with a 0.5 s acquisition time.  
The luminescence (RLU) values for control cells ranged from 5000 to 20000 RLU in all 
experiments, and were scaled by a factor of 0.001 to plot all graphs. 
 
Caspase 3/7 activity 
The cells were seeded in 96-well tissue culture plates (Corning #3585) in 100 l at a density of 
25,000 cells per well.  After 48 h, 20-80 l of medium was removed from each well and 
replaced with 20 l of each compound diluted to 6X of the final concentration in the culture 
medium to produce a final volume of 120 l.  The cells were incubated at 37 C in 5% CO2 
atmosphere for a time ranging from 15 min to 24 h.  The medium was removed and 
immediately replaced with 50 l of Apo-ONE homogenous caspase-3/7 assay reagent diluted in 
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buffer according to the manufacturer’s protocol (Promega #G7790).  The samples were 
incubated for 18 h at room temperature in the dark.  The fluorescence was measured using a 
SpectraMax M5 microplate reader with a 0.5 s acquisition time.  The fluorescence values (RFU) 
for control cells ranged from 500 to 1000 RFU in all experiments and were scaled by a factor of 
0.001 to plot all graphs. 
 
Extracellular cholesterol associated with cells 
The cells were seeded in 96-well tissue culture plates (Corning #3585) in 100 l at a density of 
100,000 cells per well.    After 48 h, 60 l of medium was removed from each well and replaced 
with 10 l of each compound diluted to 6X of the final concentration in the culture medium to 
produce a final volume of 60 l.   The cells were incubated at 37 C in 5% CO2 atmosphere for 4 
h.  The medium was removed and replaced with 50 l serum-free medium supplemented with 5 
μg/mL apoA-I (without or with 50 M glibemclamide to detect ABCA1 transporter-dependent 
efflux) for either 30 sec or 1 h at 37 C in 5% CO2 atmosphere.  After the indicated time, the 
supernatant, was transferred to a new 96-well plate and a fluorometric-based cholesterol 
detection reagent (Cayman #10007640) was added.    
 
Cholesterol efflux  
The cells were seeded in 96-well tissue culture plates (Corning #3585) in 100 l  at a density of 
100,000 cells per well.  After 48 h, the medium was removed and replaced with 50 l serum-
free medium supplemented with 5μg/mL apoA-I. After the indicated time, the supernatant 
containing the effluxed cholesterol, was transferred to a new 96-well plate.  A cholesterol 
detection reagent (Cayman #10007640) consisting of cholesterol assay buffer, cholesterol assay 
detector (10-acetyl-3,7-dihydroxyphenoxazine [ADHP]), horseradish peroxidase, cholesterol 
oxidase, and cholesterol esterase was added, and the reactions were incubated for 30 min at 37 
C.  The resazurin fluorescence intensities were measured using 555 nm excitation and 590 nm 
emission wavelengths. The cholesterol concentrations were calculated by interpolation between 
the values produced by cholesterol standards that were analyzed in parallel.   
To measure the ATP levels in the same cells that were used to measure cholesterol 
efflux, 100 μl of CellTiter-Glo luminescence cell viability reagent (Promega #G7572) was 
added, and the cells were lysed by agitation at room temperature for 20 min in the dark.  The 
luminescence was measured using a SpectraMax M5 microplate reader (Molecular Devices) 
with a 0.5 s acquisition time.  The luminescence (RLU) values for control cells ranged from 
5000 to 20000 RLU in all experiments, and were scaled by a factor of 0.001 to plot all graphs. 
 
Cortisol secretion 
The cells were seeded in 96-well tissue culture plates (Corning #3585) in 100 l at a density of 
100,000 cells per well.  After 48 h, the medium was removed and replaced with 50 l of fresh 
medium.  After the indicated incubation time, aliquots of the supernatant ranging from 0.5 to 10 
l were diluted in 50 l of medium were used to measure the amount of cortisol secreted.  
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Cortisol detection and quantification were performed by indirect ELISA according to the 
manufacturer’s protocol (Arbor Assays #K003).  
 
Doxorubicin clearance 
The cells were seeded in 96-well ibiTreat -Plates (Ibidi #89626) in 100 l at a density of 
50,000 cells per well.  After 48 h, 40-60 l of medium was removed from each well and 
replaced with 20 l of 150 M doxorubicin and the indicated compounds diluted to 6X of the 
final concentration in the culture medium, to produce a final volume of 120 l (final 
doxorubicin concentration of 25 M).  The cells were incubated at 37 C in 5% CO2 atmosphere 
until significant doxorubicin accumulation could be detected in the ATR-101 treated samples 
relative to control samples (2 h).  The medium was removed and immediately replaced with 100 
l of fresh media and intracellular doxorubicin fluorescence was visualized by fluorescence 
microscopy using a 20X objective.   
 
Transcript measurement   
H295R cells were seeded in 6-well tissue culture plates (Corning #3506) at a density of 5 X105 
per well.  After 48 h, the compound(s) indicated were added, and the cells were cultured for the 
indicated time.  The cells were harvested in 1.35 ml culture medium with trypsin.  The cells 
were collected by centrifugation and lysed in 350 l of RLT buffer (Qiagen) with -
mercaptoethanol.  mRNA extraction and DNase treatment were performed according to the 
manufacturer’s protocol (Qiagen).  All RNA samples had 260/280 ratios greater than 1.5.  The 
same amount of RNA ranging from 0.1 to 0.5 g was used for reverse transcription using the 
Roche Transcriptor First Strand cDNA synthesis kit (Roche #04897030001) using the 
manufacturer’s protocol.  SYBR Green I-based real-time qPCR assays were performed using a 
Roche LightCycler480 instrument.  The levels of transcripts in different samples were 
normalized by the levels of RPL9 transcripts. 
 
Molecular docking simulations 
A web-based docking engine (http://swissdock.eu) was used to simulate ATR-101 and 
PD129337 binding to LXR (PDB ID: 1UHL).  ChemBioOffice was used to create mol2 files 
of the compounds for docking.  The UCSF Chimera dockprep plugin was used to prepare PDB 








Table S1. Primer sequences used for qPCR 
gene  forward primer reverse primer 
ABCA1 ACAATCCTGCAGTGCTTCCT GGCAGGTACAGCGTGAAGTAG 
ABCG1 TGCTTCCACACTGTTGTCCT CTTGACCATTTCCCTTCTGC 
IDOL CGAGGACTGCCTCAACCA TGCAGTCCAAAATAGTCAACTTCT
ACTHR  CATGGGCTATCTCAAGCCAC GAGATCTTCCTGGTGTGGGATC 
CYP17A1 GCATCATAGACAACCTGAGCAA GGGTTTTGTTGGGGAAAATC 
SULT2A1 AAGCTGATCTGCCTGTAGCTG TGGTGTGAGGGTTTCAACTG 
HSD3B2 CCAGTAGCATAGAGGTAGCC TCAGATTCCACCCGTTAGC 
CYP21A2 TTGTGGACATGATTCCCTTTC CTGCTTCTCCTCGTTGTGGT 




Table Analyzed 1B. ATP level vs. time, +ATR-101 or PD129337
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 15.5 <0.0001 **** Yes
Row Factor 41.23 <0.0001 **** Yes
Column Factor 40.78 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 48890256 4 12222564 F (4, 40) = 62.25 P<0.0001
Row Factor 130027513 4 32506878 F (4, 40) = 165.6 P<0.0001
Column Factor 128634753 1 128634753 F (1, 40) = 655.2 P<0.0001
Residual 7853620 40 196340
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO - ATR-101
    0.25 382.7 -372.9 to 1138 No ns 0.6285
    0.5 2192 1436 to 2947 Yes **** <0.0001
    1 3196 2441 to 3952 Yes **** <0.0001
    2 3886 3130 to 4642 Yes **** <0.0001
    4 6383 5627 to 7139 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO - ATR-101
    0.25 10294 9911 382.7 280.2 5 5 1.366 40
    0.5 10067 7876 2192 280.2 5 5 7.82 40
    1 9578 6382 3196 280.2 5 5 11.41 40
    2 9006 5120 3886 280.2 5 5 13.87 40
    4 8582 2199 6383 280.2 5 5 22.78 40
Table Analyzed 1B. Caspase activity vs. time, +ATR-101 or PD129337
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 5.289 0.0019 ** Yes
Row Factor 30.3 <0.0001 **** Yes
Column Factor 54.14 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 445165 4 111291 F (4, 40) = 5.149 P=0.0019
Row Factor 2550285 4 637571 F (4, 40) = 29.5 P<0.0001
Column Factor 4557453 1 4557453 F (1, 40) = 210.9 P<0.0001
Residual 864565 40 21614
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 5
Alpha 0.05
2way ANOVA of 1B. ATP level vs. time, +ATR-101 or PD129337
2way ANOVA of 1B. Caspase activity vs. time, +ATR-101 or PD129337
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO - ATR-101
0.25 h -361.3 -612 to -110.6 Yes ** 0.0019
0.5 h -433.5 -684.3 to -182.8 Yes *** 0.0002
1 h -599.5 -850.2 to -348.8 Yes **** <0.0001
2 h -772 -1023 to -521.3 Yes **** <0.0001
4 h -852.7 -1103 to -602 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO - ATR-101
0.25 h 2080 2441 -361.3 92.98 5 5 3.886 40
0.5 h 2116 2550 -433.5 92.98 5 5 4.663 40
1 h 2193 2792 -599.5 92.98 5 5 6.448 40
2 h 2353 3125 -772 92.98 5 5 8.303 40
4 h 2417 3270 -852.7 92.98 5 5 9.17 40
Table Analyzed 1D. H295R ATP level vs. ATR-101 or PD129337 concentration, 4 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 32.49 <0.0001 **** Yes
Row Factor 40.57 <0.0001 **** Yes
Column Factor 14.63 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 118800799 6 19800133 F (6, 98) = 43.11 P<0.0001
Row Factor 148380193 6 24730032 F (6, 98) = 53.84 P<0.0001
Column Factor 53508617 1 53508617 F (1, 98) = 116.5 P<0.0001
Residual 45010766 98 459294
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 7
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101 - PD129337
    0 363.3 -565.2 to 1292 No ns 0.9057
    5 107 -821.5 to 1035 No ns >0.9999
    10 215.6 -712.9 to 1144 No ns 0.9946
    20 51.4 -877.1 to 979.9 No ns >0.9999
    40 -1404 -2333 to -476 Yes *** 0.0005
    60 -4101 -5029 to -3172 Yes **** <0.0001
    100 -4909 -5837 to -3980 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101 - PD129337
    0 11084 10721 363.3 338.9 8 8 1.072 98
    5 10650 10543 107 338.9 8 8 0.3156 98
    10 10777 10561 215.6 338.9 8 8 0.6361 98
    20 10676 10625 51.4 338.9 8 8 0.1517 98
    40 9018 10422 -1404 338.9 8 8 4.145 98
    60 6367 10467 -4101 338.9 8 8 12.1 98
    100 5338 10247 -4909 338.9 8 8 14.49 98
2way ANOVA of 1D. H295R ATP level vs. ATR-101 or PD129337, 4 h
2way ANOVA 1D. H295R caspase activity vs. ATR-101 or PD129337, 4h
Table Analyzed 1D. H295R caspase activity vs. ATR-101 or PD129337 concentration, 4 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 32.05 <0.0001 **** Yes
Row Factor 31.17 <0.0001 **** Yes
Column Factor 34.46 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 11845810 6 1974302 F (6, 98) = 225.5 P<0.0001
Row Factor 11519967 6 1919994 F (6, 98) = 219.3 P<0.0001
Column Factor 12736858 1 12736858 F (1, 98) = 1455 P<0.0001
Residual 857839 98 8753
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 7
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101 - PD129337
    0 22.67 -105.5 to 150.8 No ns 0.999
    5 52.03 -76.15 to 180.2 No ns 0.8882
    10 57.67 -70.51 to 185.8 No ns 0.8253
    20 409.6 281.4 to 537.8 Yes **** <0.0001
    40 1125 997.2 to 1254 Yes **** <0.0001
    60 1382 1254 to 1510 Yes **** <0.0001
    100 1672 1543 to 1800 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101 - PD129337
    0 1037 1014 22.67 46.78 8 8 0.4845 98
    5 1091 1039 52.03 46.78 8 8 1.112 98
    10 1110 1052 57.67 46.78 8 8 1.233 98
    20 1423 1013 409.6 46.78 8 8 8.755 98
    40 2136 1010 1125 46.78 8 8 24.06 98
    60 2420 1038 1382 46.78 8 8 29.55 98
    100 2687 1016 1672 46.78 8 8 35.73 98
Table Analyzed 1D. BD140C ATP level vs. ATR-101 or PD129337 concentration, 4 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 21.45 <0.0001 **** Yes
Row Factor 24.99 <0.0001 **** Yes
Column Factor 41.76 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 42381243 5 8476249 F (5, 60) = 21.81 P<0.0001
Row Factor 49384400 5 9876880 F (5, 60) = 25.41 P<0.0001
Column Factor 82532640 1 82532640 F (1, 60) = 212.4 P<0.0001
Residual 23318048 60 388634
Number of missing values 0
Compare each cell mean with the other cell mean in that row
2way ANOVA of 1D. BD140C ATP level vs. ATR-101 or PD129337, 4 h
Number of families 1
Number of comparisons per family 6
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101 - PD129337
    0 -144.8 -1124 to 834.4 No ns 0.9991
    5 -446.8 -1426 to 532.4 No ns 0.7736
    10 -1660 -2640 to -681.2 Yes *** 0.0001
    20 -2716 -3695 to -1737 Yes **** <0.0001
    40 -3595 -4574 to -2616 Yes **** <0.0001
    100 -4285 -5264 to -3306 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101 - PD129337
    0 6717 6862 -144.8 359.9 6 6 0.4023 60
    5 6269 6716 -446.8 359.9 6 6 1.241 60
    10 5115 6775 -1660 359.9 6 6 4.613 60
    20 3901 6617 -2716 359.9 6 6 7.546 60
    40 3084 6679 -3595 359.9 6 6 9.988 60
    100 2378 6663 -4285 359.9 6 6 11.91 60
Table Analyzed 1D. BD140C caspase activity vs. ATR-101 or PD129337 concentration, 4 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 31.43 <0.0001 **** Yes
Row Factor 31.32 <0.0001 **** Yes
Column Factor 34.97 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 5574417 4 1393604 F (4, 50) = 172.8 P<0.0001
Row Factor 5553960 4 1388490 F (4, 50) = 172.2 P<0.0001
Column Factor 6202466 1 6202466 F (1, 50) = 769 P<0.0001
Residual 403263 50 8065
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101 - PD129337
    0 13.28 -125.2 to 151.7 No ns 0.9997
    5 65.31 -73.12 to 203.7 No ns 0.6993
    10 458 319.6 to 596.4 Yes **** <0.0001
    20 1090 951.9 to 1229 Yes **** <0.0001
    40 1588 1450 to 1727 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101 - PD129337
    0 1021 1008 13.28 51.85 6 6 0.2561 50
    5 1082 1017 65.31 51.85 6 6 1.26 50
    10 1498 1040 458 51.85 6 6 8.833 50
    20 2105 1015 1090 51.85 6 6 21.03 50
    40 2602 1014 1588 51.85 6 6 30.63 50
2way ANOVA of 1D. BD140C caspase activity vs. ATR-101 or PD129337, 4h
Table Analyzed 2B. ATP level vs. MBCD concentration, 4h, +ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9532
Brown-Forsythe test
F (DFn, DFd) 0.5473 (5, 24)
P value 0.7387
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 1.416
P value 0.9226
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 477591874 5 95518375 F (5, 24) = 97.79 P<0.0001
Residual (within columns) 23443645 24 976819
Total 501035519 29
Data summary
Number of treatments (columns) 6
Number of values (total) 30
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 0.25 172.4 -1512 to 1857 No ns 0.9985 B 0.25
0 vs. 0.5 -910.2 -2595 to 774.7 No ns 0.468 C 0.5
0 vs. 1 -6437 -8122 to -4752 Yes **** 0.0001 D 1
0 vs. 1.5 -8231 -9916 to -6546 Yes **** 0.0001 E 1.5
0 vs. 2 -9369 -11053 to -7684 Yes **** 0.0001 F 2
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 0.25 3416 3244 172.4 625.1 5 5 0.2758 24
0 vs. 0.5 3416 4327 -910.2 625.1 5 5 1.456 24
0 vs. 1 3416 9853 -6437 625.1 5 5 10.3 24
0 vs. 1.5 3416 11648 -8231 625.1 5 5 13.17 24
0 vs. 2 3416 12785 -9369 625.1 5 5 14.99 24
Table Analyzed 2B. Caspase activity vs. MBCD concentration, 4h, +ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.951
Brown-Forsythe test
F (DFn, DFd) 1.107 (5, 24)
P value 0.383
P value summary ns
Ordinary one-way ANOVA of 2B. ATP level vs. MBCD concentration, 4h, +ATR-101
Ordinary one-way ANOVA of 2B. Caspase activity vs. MBCD concentration, +ATR-101,
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 18.9
P value 0.002
P value summary **
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 39075912 5 7815182 F (5, 24) = 93.22 P<0.0001
Residual (within columns) 2012102 24 83838
Total 41088014 29
Data summary
Number of treatments (columns) 6
Number of values (total) 30
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 0.25 -154.4 -648 to 339.2 No ns 0.8659 B 0.25
0 vs. 0.5 1101 607.9 to 1595 Yes **** 0.0001 C 0.5
0 vs. 1 2132 1638 to 2625 Yes **** 0.0001 D 1
0 vs. 1.5 2547 2053 to 3040 Yes **** 0.0001 E 1.5
0 vs. 2 2626 2132 to 3120 Yes **** 0.0001 F 2
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 0.25 3632 3787 -154.4 183.1 5 5 0.8433 24
0 vs. 0.5 3632 2531 1101 183.1 5 5 6.015 24
0 vs. 1 3632 1501 2132 183.1 5 5 11.64 24
0 vs. 1.5 3632 1086 2547 183.1 5 5 13.91 24
0 vs. 2 3632 1006 2626 183.1 5 5 14.34 24
Table Analyzed 2D. ATP level vs. cholesterol concentration, 24 h, +ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9454
Brown-Forsythe test
F (DFn, DFd) 0.0787 (5, 24)
P value 0.9949
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 1.448
P value 0.919
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 615675479 5 123135096 F (5, 24) = 83.04 P<0.0001
Residual (within columns) 35589813 24 1482909
Total 651265291 29
Data summary
Number of treatments (columns) 6
Number of values (total) 30
Ordinary one-way ANOVA of 2D. ATP level vs. cholesterol concentration, 24 h, +AT
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 1 -2316 -4392 to -240.1 Yes * 0.0251 B 1
0 vs. 2.5 -8678 -10754 to -6602 Yes **** 0.0001 C 2.5
0 vs. 10 -11065 -13141 to -8989 Yes **** 0.0001 D 10
0 vs. 20 -11107 -13183 to -9031 Yes **** 0.0001 E 20
0 vs. 40 -11104 -13180 to -9028 Yes **** 0.0001 F 40
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 880.6 3197 -2316 770.2 5 5 3.007 24
0 vs. 2.5 880.6 9558 -8678 770.2 5 5 11.27 24
0 vs. 10 880.6 11946 -11065 770.2 5 5 14.37 24
0 vs. 20 880.6 11987 -11107 770.2 5 5 14.42 24
0 vs. 40 880.6 11985 -11104 770.2 5 5 14.42 24
Table Analyzed 2D. Caspase activity vs. cholesterol concentration, 24 h, +ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9353
Brown-Forsythe test
F (DFn, DFd) 1.273 (5, 24)
P value 0.3078
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 7.627
P value 0.178
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 92469004 5 18493801 F (5, 24) = 69.42 P<0.0001
Residual (within columns) 6394168 24 266424
Total 98863172 29
Data summary
Number of treatments (columns) 6
Number of values (total) 30
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 1 -2774 -3654 to -1895 Yes **** 0.0001 B 1
0 vs. 2.5 -111.5 -991.4 to 768.4 No ns 0.9964 C 2.5
0 vs. 10 1547 667.5 to 2427 Yes *** 0.0004 D 10
0 vs. 20 1877 997.4 to 2757 Yes **** 0.0001 E 20
0 vs. 40 2538 1658 to 3418 Yes **** 0.0001 F 40
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
Ordinary one-way ANOVA of 2D. Caspase activity vs. cholesterol concentration, 24
0 vs. 1 4391 7166 -2774 326.4 5 5 8.499 24
0 vs. 2.5 4391 4503 -111.5 326.4 5 5 0.3415 24
0 vs. 10 4391 2844 1547 326.4 5 5 4.74 24
0 vs. 20 4391 2514 1877 326.4 5 5 5.751 24
0 vs. 40 4391 1853 2538 326.4 5 5 7.776 24
Table Analyzed 2F. Insoluble external cholesterol vs. compound, 4h




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9645
Brown-Forsythe test
F (DFn, DFd) 1.841 (3, 16)
P value 0.1805
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 10.13
P value 0.0175
P value summary *
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 35.74 3 11.91 F (3, 16) = 144.8 P<0.0001
Residual (within columns) 1.316 16 0.08226
Total 37.05 19
Data summary
Number of treatments (columns) 4
Number of values (total) 20
Number of families 1
Number of comparisons per family 3
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
DMSO vs. ATR-101 -1.006 -1.477 to -0.5362 Yes *** 0.0001 B ATR-101
DMSO vs. cholesterol -1.319 -1.79 to -0.8491 Yes **** 0.0001 C cholesterol
DMSO vs. cholesterol+ATR-101 -3.65 -4.12 to -3.179 Yes **** 0.0001 D cholesterol+ATR-101
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
DMSO vs. ATR-101 0.4236 1.43 -1.006 0.1814 5 5 5.549 16
DMSO vs. cholesterol 0.4236 1.743 -1.319 0.1814 5 5 7.274 16
DMSO vs. cholesterol+ATR-101 0.4236 4.073 -3.65 0.1814 5 5 20.12 16
Table Analyzed 2F. Soluble external cholesterol vs. time




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9289
Brown-Forsythe test
F (DFn, DFd) 3.593 (4, 20)
Ordinary one-way ANOVA of 2F. Soluble external cholesterol vs. time
Ordinary one-way ANOVA of 2F. Insoluble external cholesterol vs. compound, 4h
P value 0.023
P value summary *
Are SDs significantly different (P < 0.05)? Yes
Bartlett's test
Bartlett's statistic (corrected) 17.09
P value 0.0019
P value summary **
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 25.21 4 6.302 F (4, 20) = 65.3 P<0.0001
Residual (within columns) 1.93 20 0.0965
Total 27.14 24
Data summary
Number of treatments (columns) 5
Number of values (total) 25
Number of families 1
Number of comparisons per family 4
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 1 -0.389 -0.9099 to 0.1318 No ns 0.1817 B 1
0 vs. 2 -0.8909 -1.412 to -0.37 Yes *** 0.0008 C 2
0 vs. 4 -1.957 -2.478 to -1.436 Yes **** 0.0001 D 4
0 vs. 6 -2.708 -3.229 to -2.188 Yes **** 0.0001 E 6
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 0.4231 0.8121 -0.389 0.1965 5 5 1.98 20
0 vs. 2 0.4231 1.314 -0.8909 0.1965 5 5 4.535 20
0 vs. 4 0.4231 2.38 -1.957 0.1965 5 5 9.961 20
0 vs. 6 0.4231 3.132 -2.708 0.1965 5 5 13.79 20
Table Analyzed 3B. ATP level vs. MBCD, serum-free media, +ATR-101





P value summary ****
Significantly different (P < 0.05)? Yes
One- or two-tailed P value? Two-tailed
t, df t=18.73 df=14
How big is the difference?
Mean ± SEM of column A 5415 ± 164.5, n=8
Mean ± SEM of column B 13145 ± 378.4, n=8
Difference between means 7730 ± 412.6
95% confidence interval 6845 to 8615
R squared (eta squared) 0.9616
F test to compare variances
F, DFn, Dfd 5.29, 7, 7
P value 0.043
P value summary *
Significantly different (P < 0.05)? Yes
Table Analyzed 3B. Caspase activity vs. MBCD, serum-free media, +ATR-101





P value summary ***
Significantly different (P < 0.05)? Yes
One- or two-tailed P value? Two-tailed
t, df t=5.573 df=10
How big is the difference?
Mean ± SEM of column A 2197 ± 65.23, n=6
Mean ± SEM of column B 1736 ± 50.83, n=6
Difference between means -460.9 ± 82.7
95% confidence interval -645.1 to -276.6
R squared (eta squared) 0.7565
F test to compare variances
F, DFn, Dfd 1.647, 5, 5
P value 0.5975
P value summary ns
Significantly different (P < 0.05)? No
Table Analyzed 3C. Cholesterol efflux vs. time, +ATR-101 or DMSO
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 30.16 <0.0001 **** Yes
Row Factor 41.15 <0.0001 **** Yes
Column Factor 22.61 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 3493071 4 873268 F (4, 50) = 62 P<0.0001
Row Factor 4765266 4 1191317 F (4, 50) = 84.58 P<0.0001
Column Factor 2618092 1 2618092 F (1, 50) = 185.9 P<0.0001
Residual 704234 50 14085
Unpaired t test of 3B. ATP level vs. MBCD, serum-free media, +ATR-101
2way ANOVA of 3C. Cholesterol efflux vs. time, +ATR-101 or DMSO
Unpaired t test of 3B. Caspase activity vs. MBCD, serum-free media, +ATR-101
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO - ATR-101
    0.25 -25.72 -208.7 to 157.2 No ns 0.9979
    0.5 37.93 -145 to 220.9 No ns 0.9873
    1 175.4 -7.508 to 358.4 No ns 0.0658
    2 636.9 454 to 819.9 Yes **** <0.0001
    4 1264 1081 to 1447 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO - ATR-101
    0.25 -102.5 -76.76 -25.72 68.52 6 6 0.3754 50
    0.5 -36.77 -74.7 37.93 68.52 6 6 0.5536 50
    1 141.9 -33.5 175.4 68.52 6 6 2.56 50
    2 573.4 -63.51 636.9 68.52 6 6 9.296 50
    4 1310 45.91 1264 68.52 6 6 18.45 50
Table Analyzed 3C. ATP level vs. time, +ATR-101 or DMSO
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 14.26 <0.0001 **** Yes
Row Factor 42.94 <0.0001 **** Yes
Column Factor 20.48 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 92346410 4 23086603 F (4, 50) = 7.989 P<0.0001
Row Factor 278007030 4 69501757 F (4, 50) = 24.05 P<0.0001
Column Factor 132583040 1 132583040 F (1, 50) = 45.88 P<0.0001
Residual 144481981 50 2889640
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO - ATR-101
    0.25 -254.6 -2875 to 2366 No ns 0.9997
    0.5 1284 -1336 to 3905 No ns 0.6654
    1 3133 512.7 to 5753 Yes * 0.0121
    2 3594 973.4 to 6214 Yes ** 0.003
    4 7108 4488 to 9729 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO - ATR-101
    0.25 17814 18068 -254.6 981.4 6 6 0.2594 50
    0.5 18676 17392 1284 981.4 6 6 1.309 50
    1 18080 14947 3133 981.4 6 6 3.192 50
    2 16711 13117 3594 981.4 6 6 3.662 50
    4 15834 8726 7108 981.4 6 6 7.243 50
2way ANOVA of 3C. ATP level vs. time, +ATR-101 or DMSO
Table Analyzed 3D. Cholesterol efflux vs. ATR-101 concentration




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.92
Brown-Forsythe test
F (DFn, DFd) 7.456 (6, 35)
P value <0.0001
P value summary ****
Are SDs significantly different (P < 0.05)? Yes
Bartlett's test
Bartlett's statistic (corrected) 14.97
P value 0.0205
P value summary *
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 7175657 6 1195943 F (6, 35) = 67.06 P<0.0001
Residual (within columns) 624209 35 17835
Total 7799866 41
Data summary
Number of treatments (columns) 7
Number of values (total) 42
Number of families 1
Number of comparisons per family 6
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 5 13.07 -194.9 to 221 No ns 0.9997 B 5
0 vs. 10 46.01 -162 to 254 No ns 0.9785 C 10
0 vs. 20 318.4 110.5 to 526.4 Yes ** 0.0012 D 20
0 vs. 40 502.4 294.4 to 710.3 Yes **** 0.0001 E 40
0 vs. 60 823.2 615.2 to 1031 Yes **** 0.0001 F 60
0 vs. 100 1152 943.8 to 1360 Yes **** 0.0001 G 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 5 1402 1389 13.07 77.1 6 6 0.1695 35
0 vs. 10 1402 1356 46.01 77.1 6 6 0.5967 35
0 vs. 20 1402 1083 318.4 77.1 6 6 4.13 35
0 vs. 40 1402 899.5 502.4 77.1 6 6 6.516 35
0 vs. 60 1402 578.8 823.2 77.1 6 6 10.68 35
0 vs. 100 1402 250.2 1152 77.1 6 6 14.94 35
Table Analyzed 3D. Cholesterol efflux vs. PD129337 concentration




P value summary ns
Significant diff. among means (P < 0.05)? No
R square 0.1165
Brown-Forsythe test
F (DFn, DFd) 0.1936 (6, 35)
P value 0.9766
P value summary ns
Are SDs significantly different (P < 0.05)? No
Ordinary one-way ANOVA of 3D. Cholesterol efflux vs. PD129337 concentration
Ordinary one-way ANOVA of 3D. Cholesterol efflux vs. ATR-101 concentration
Bartlett's test
Bartlett's statistic (corrected) 2.454
P value 0.8735
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 41572 6 6929 F (6, 35) = 0.7695 P=0.5990
Residual (within columns) 315127 35 9004
Total 356699 41
Data summary
Number of treatments (columns) 7
Number of values (total) 42
Number of families 1
Number of comparisons per family 6
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 5 -33.5 -181.3 to 114.3 No ns 0.9759 B 5
0 vs. 10 -19.3 -167.1 to 128.5 No ns 0.998 C 10
0 vs. 20 -92.71 -240.5 to 55.05 No ns 0.3604 D 20
0 vs. 40 -66.35 -214.1 to 81.41 No ns 0.6798 E 40
0 vs. 60 -7.596 -155.4 to 140.2 No ns 0.9998 F 60
0 vs. 100 -14.82 -162.6 to 132.9 No ns 0.9996 G 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 5 1353 1387 -33.5 54.78 6 6 0.6115 35
0 vs. 10 1353 1372 -19.3 54.78 6 6 0.3524 35
0 vs. 20 1353 1446 -92.71 54.78 6 6 1.692 35
0 vs. 40 1353 1419 -66.35 54.78 6 6 1.211 35
0 vs. 60 1353 1361 -7.596 54.78 6 6 0.1386 35
0 vs. 100 1353 1368 -14.82 54.78 6 6 0.2705 35
Table Analyzed 3D. Cholesterol efflux vs. glibenclamide concentration




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9927
Brown-Forsythe test
F (DFn, DFd) 2.284 (5, 30)
P value 0.0714
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 7.631
P value 0.1778
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 11451678 5 2290336 F (5, 30) = 817.7 P<0.0001
Residual (within columns) 84032 30 2801
Total 11535710 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Ordinary one-way ANOVA of 3D.  Cholesterol efflux vs. glibenclamide concentratio
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 50 1408 1327 to 1489 Yes **** 0.0001 B 50
0 vs. 150 1514 1433 to 1595 Yes **** 0.0001 C 150
0 vs. 300 1502 1420 to 1583 Yes **** 0.0001 D 300
0 vs. 450 1565 1484 to 1646 Yes **** 0.0001 E 450
0 vs. 600 1549 1468 to 1630 Yes **** 0.0001 F 600
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 50 1397 -10.35 1408 30.56 6 6 46.07 30
0 vs. 150 1397 -116.4 1514 30.56 6 6 49.54 30
0 vs. 300 1397 -104.3 1502 30.56 6 6 49.14 30
0 vs. 450 1397 -167.3 1565 30.56 6 6 51.21 30
0 vs. 600 1397 -151.9 1549 30.56 6 6 50.7 30
Table Analyzed 3D. ATP level vs. ATR-101 concentration, serum-free media




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.8772
Brown-Forsythe test
F (DFn, DFd) 2.223 (6, 35)
P value 0.0639
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 7.19
P value 0.3037
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 60144755 6 10024126 F (6, 35) = 41.68 P<0.0001
Residual (within columns) 8417575 35 240502
Total 68562329 41
Data summary
Number of treatments (columns) 7
Number of values (total) 42
Number of families 1
Number of comparisons per family 6
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 5 401.8 -361.9 to 1165 No ns 0.5334 B 5
0 vs. 10 763.3 -0.3403 to 1527 No ns 0.0501 C 10
0 vs. 20 1220 455.9 to 1983 Yes *** 0.0007 D 20
0 vs. 40 2105 1341 to 2869 Yes **** 0.0001 E 40
0 vs. 60 2556 1792 to 3320 Yes **** 0.0001 F 60
0 vs. 100 3614 2850 to 4378 Yes **** 0.0001 G 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 5 8589 8187 401.8 283.1 6 6 1.419 35
0 vs. 10 8589 7826 763.3 283.1 6 6 2.696 35
0 vs. 20 8589 7369 1220 283.1 6 6 4.307 35
0 vs. 40 8589 6484 2105 283.1 6 6 7.434 35
Ordinary one-way ANOVA of 3D. ATP levels vs. ATR-101 concentration, serum free m
0 vs. 60 8589 6033 2556 283.1 6 6 9.027 35
0 vs. 100 8589 4975 3614 283.1 6 6 12.76 35
Table Analyzed 3D. ATP level vs. PD129337 concentration, serum-free media




P value summary ns
Significant diff. among means (P < 0.05)? No
R square 0.1049
Brown-Forsythe test
F (DFn, DFd) 0.001965 (6, 35)
P value >0.9999
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.1173
P value >0.9999
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 231107 6 38518 F (6, 35) = 0.6836 P=0.6639
Residual (within columns) 1972087 35 56345
Total 2203195 41
Data summary
Number of treatments (columns) 7
Number of values (total) 42
Number of families 1
Number of comparisons per family 6
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 5 120.1 -249.5 to 489.7 No ns 0.8875 B 5
0 vs. 10 2.009 -367.6 to 371.6 No ns 0.9999 C 10
0 vs. 20 -83.31 -452.9 to 286.3 No ns 0.9766 D 20
0 vs. 40 109.6 -260 to 479.3 No ns 0.9214 E 40
0 vs. 60 39.03 -330.6 to 408.7 No ns 0.9996 F 60
0 vs. 100 136.3 -233.3 to 506 No ns 0.8231 G 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 5 8465 8345 120.1 137 6 6 0.8764 35
0 vs. 10 8465 8463 2.009 137 6 6 0.01466 35
0 vs. 20 8465 8549 -83.31 137 6 6 0.6079 35
0 vs. 40 8465 8356 109.6 137 6 6 0.7999 35
0 vs. 60 8465 8426 39.03 137 6 6 0.2848 35
0 vs. 100 8465 8329 136.3 137 6 6 0.9948 35
Table Analyzed 3D. ATP level vs. glibenclamide concentration, serum-free media




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9157
Brown-Forsythe test
F (DFn, DFd) 0.002474 (5, 30)
Ordinary one-way ANOVA of 3D. ATP levels vs. glibenclamide concentration, serum-
Ordinary one-way ANOVA of 3D. ATP levels vs. PD129337 concentration, serum-free 
P value >0.9999
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.2514
P value 0.9985
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 22703932 5 4540786 F (5, 30) = 65.19 P<0.0001
Residual (within columns) 2089635 30 69654
Total 24793566 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 50 -164.4 -569.3 to 240.4 No ns 0.722 B 50
0 vs. 150 10.96 -393.9 to 415.8 No ns 0.9999 C 150
0 vs. 300 -67.8 -472.7 to 337.1 No ns 0.9893 D 300
0 vs. 450 583.5 178.7 to 988.4 Yes ** 0.0028 E 450
0 vs. 600 2104 1699 to 2508 Yes **** 0.0001 F 600
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 50 8515 8679 -164.4 152.4 6 6 1.079 30
0 vs. 150 8515 8504 10.96 152.4 6 6 0.0719 30
0 vs. 300 8515 8583 -67.8 152.4 6 6 0.445 30
0 vs. 450 8515 7931 583.5 152.4 6 6 3.829 30
0 vs. 600 8515 6411 2104 152.4 6 6 13.81 30
Table Analyzed 3E. Cholesterol efflux vs. ATR-101 concentration, +olesoxime or DMSO
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 0.5951 0.4837 ns No
Row Factor 89.77 <0.0001 **** Yes
Column Factor 1.164 0.0116 * Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 43941 4 10985 F (4, 50) = 0.8782 P=0.4837
Row Factor 6628615 4 1657154 F (4, 50) = 132.5 P<0.0001
Column Factor 85927 1 85927 F (1, 50) = 6.869 P=0.0116
Residual 625448 50 12509
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO - Olesoxime
    0 -104.8 -277.2 to 67.56 No ns 0.4439
    12.5 -57.55 -230 to 114.9 No ns 0.9062
    25 12.09 -160.3 to 184.5 No ns >0.9999
    50 -76.53 -248.9 to 95.87 No ns 0.749
2way ANOVA of 3E. Cholesterol efflux vs. ATR-101 concentration, +olesoxime or DM
    100 -151.6 -324 to 20.81 No ns 0.1093
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO - Olesoxime
    0 1802 1907 -104.8 64.57 6 6 1.624 50
    12.5 1102 1160 -57.55 64.57 6 6 0.8913 50
    25 982.9 970.9 12.09 64.57 6 6 0.1873 50
    50 948.4 1025 -76.53 64.57 6 6 1.185 50
    100 969.6 1121 -151.6 64.57 6 6 2.348 50
Table Analyzed 3E. ATP level vs. ATR-101 concentration, +olesoxime or DMSO
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 7.125 <0.0001 **** Yes
Row Factor 85.49 <0.0001 **** Yes
Column Factor 4.682 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 87336244 4 21834061 F (4, 80) = 52.78 P<0.0001
Row Factor 1047881833 4 261970458 F (4, 80) = 633.3 P<0.0001
Column Factor 57392114 1 57392114 F (1, 80) = 138.7 P<0.0001
Residual 33092617 80 413658
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO - Olesoxime
    0 391.6 -406.1 to 1189 No ns 0.6728
    12.5 -1531 -2329 to -733.6 Yes **** <0.0001
    25 -5289 -6087 to -4491 Yes **** <0.0001
    50 -1267 -2065 to -469.2 Yes *** 0.0004
    100 -289.8 -1088 to 507.9 No ns 0.8767
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO - Olesoxime
    0 10492 10100 391.6 303.2 9 9 1.292 80
    12.5 7367 8898 -1531 303.2 9 9 5.051 80
    25 2786 8075 -5289 303.2 9 9 17.44 80
    50 1563 2830 -1267 303.2 9 9 4.179 80
    100 1188 1478 -289.8 303.2 9 9 0.9558 80
2way ANOVA of 3E. ATP level vs. ATR-101 concentration, +olesoxime or DMSO
Table Analyzed 4A. Cortisol secretion vs. time, +ATR-101 or DMSO, +forskolin or DMSO
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 41.3 <0.0001 **** Yes
Row Factor 31.73 <0.0001 **** Yes
Column Factor 23.06 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 442452 3 147484 F (3, 32) = 112.8 P<0.0001
Row Factor 339943 3 113314 F (3, 32) = 86.64 P<0.0001
Column Factor 247018 1 247018 F (1, 32) = 188.9 P<0.0001
Residual 41853 32 1308
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 4
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO - ATR-101
    0.25 -15 -75.36 to 45.36 No ns 0.9454
    1 19.04 -41.32 to 79.39 No ns 0.88
    4 112.2 51.82 to 172.5 Yes *** 0.0001
    8 512.5 452.1 to 572.8 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO - ATR-101
    0.25 82.15 97.15 -15 22.87 5 5 0.6559 32
    1 102.7 83.65 19.04 22.87 5 5 0.8323 32
    4 198.4 86.2 112.2 22.87 5 5 4.904 32
    8 572 59.54 512.5 22.87 5 5 22.4 32
Table Analyzed 4A. Cortisol secretion vs. time, +ATR-101 or DMSO, +forskolin or DMSO
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 37.52 <0.0001 **** Yes
Row Factor 34.43 <0.0001 **** Yes
Column Factor 25.18 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 1274022 3 424674 F (3, 32) = 139.7 P<0.0001
Row Factor 1169056 3 389685 F (3, 32) = 128.2 P<0.0001
Column Factor 855130 1 855130 F (1, 32) = 281.3 P<0.0001
Residual 97274 32 3040
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 4
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
2way ANOVA of 4A. Cortisol secretion vs. time, +ATR-101 or DMSO, +forskolin
2way ANOVA of 4A. Cortisol secretion vs. time, +ATR-101 or DMSO, +DMSO
DMSO+forskolin - ATR-101+forskolin
    0.25 -9.815 -101.8 to 82.2 No ns 0.9977
    1 20.46 -71.56 to 112.5 No ns 0.963
    4 280 188 to 372 Yes **** <0.0001
    8 879.1 787 to 971.1 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO+forskolin - ATR-101+forskolin
    0.25 75.49 85.3 -9.815 34.87 5 5 0.2815 32
    1 106.3 85.8 20.46 34.87 5 5 0.5869 32
    4 376.4 96.37 280 34.87 5 5 8.03 32
    8 946.2 67.12 879.1 34.87 5 5 25.21 32
Table Analyzed 4B. Cortisol secretion vs. ATR-101 or PD129337 concentration
Two-way RM ANOVA Matching: Stacked
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 44.81 <0.0001 **** Yes
Time 7.813 <0.0001 **** Yes
Column Factor 34.81 <0.0001 **** Yes
Subjects (matching) 6.469 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 106416 5 21283 F (5, 50) = 73.41 P<0.0001
Time 18558 5 3712 F (5, 50) = 12.8 P<0.0001
Column Factor 82673 1 82673 F (1, 10) = 53.81 P<0.0001
Subjects (matching) 15364 10 1536 F (10, 50) = 5.299 P<0.0001
Residual 14496 50 289.9
Number of missing values 0
Within each column, compare rows (simple effects within columns)
Number of families 2
Number of comparisons per family 5
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101
0 vs. 1 -17.06 -43.31 to 9.187 No ns 0.372
0 vs. 10 6.291 -19.96 to 32.54 No ns 0.9759
0 vs. 20 36.26 10.01 to 62.51 Yes ** 0.0028
0 vs. 35 99.84 73.59 to 126.1 Yes **** <0.0001
0 vs. 100 126.6 100.3 to 152.8 Yes **** <0.0001
PD129337
0 vs. 1 -3.142 -29.39 to 23.11 No ns 0.999
0 vs. 10 -23.82 -50.07 to 2.428 No ns 0.0917
0 vs. 20 -46.07 -72.31 to -19.82 Yes *** 0.0001
0 vs. 35 -47.13 -73.38 to -20.88 Yes **** <0.0001
0 vs. 100 -69.67 -95.92 to -43.43 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101
0 vs. 1 195.3 212.3 -17.06 9.831 6 6 1.735 50
0 vs. 10 195.3 189 6.291 9.831 6 6 0.6399 50
0 vs. 20 195.3 159 36.26 9.831 6 6 3.689 50
0 vs. 35 195.3 95.44 99.84 9.831 6 6 10.16 50
0 vs. 100 195.3 68.69 126.6 9.831 6 6 12.88 50
2way ANOVA of 4B. Cortisol secretion vs. ATR-101 or PD129337 concentration
PD129337
0 vs. 1 189.4 192.6 -3.142 9.831 6 6 0.3196 50
0 vs. 10 189.4 213.2 -23.82 9.831 6 6 2.423 50
0 vs. 20 189.4 235.5 -46.07 9.831 6 6 4.686 50
0 vs. 35 189.4 236.6 -47.13 9.831 6 6 4.794 50
0 vs. 100 189.4 259.1 -69.67 9.831 6 6 7.087 50
Table Analyzed 4B. ATP level vs. ATR-101 or PD129337 concentration
Two-way RM ANOVA Matching: Stacked
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 46.09 <0.0001 **** Yes
Time 28.65 <0.0001 **** Yes
Column Factor 15.36 0.0022 ** Yes
Subjects (matching) 6.248 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 314667008 5 62933402 F (5, 40) = 101 P<0.0001
Time 195634263 5 39126853 F (5, 40) = 62.78 P<0.0001
Column Factor 104850250 1 104850250 F (1, 8) = 19.66 P=0.0022
Subjects (matching) 42657101 8 5332138 F (8, 40) = 8.555 P<0.0001
Residual 24931365 40 623284
Number of missing values 0
Within each column, compare rows (simple effects within columns)
Number of families 2
Number of comparisons per family 5
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101
0 vs. 1 0.962 -1345 to 1347 No ns >0.9999
0 vs. 10 734.8 -611.5 to 2081 No ns 0.5535
0 vs. 20 802 -544.4 to 2148 No ns 0.4605
0 vs. 35 4141 2795 to 5487 Yes **** <0.0001
0 vs. 100 11431 10085 to 12778 Yes **** <0.0001
PD129337
0 vs. 1 551.2 -795.1 to 1898 No ns 0.8014
0 vs. 10 -125.4 -1472 to 1221 No ns 0.9997
0 vs. 20 -429.9 -1776 to 916.4 No ns 0.9185
0 vs. 35 -281.8 -1628 to 1065 No ns 0.9862
0 vs. 100 -1296 -2642 to 50.84 No ns 0.0642
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101
0 vs. 1 17173 17172 0.962 499.3 5 5 0.001927 40
0 vs. 10 17173 16438 734.8 499.3 5 5 1.472 40
0 vs. 20 17173 16371 802 499.3 5 5 1.606 40
0 vs. 35 17173 13032 4141 499.3 5 5 8.293 40
0 vs. 100 17173 5742 11431 499.3 5 5 22.89 40
PD129337
0 vs. 1 16702 16151 551.2 499.3 5 5 1.104 40
0 vs. 10 16702 16827 -125.4 499.3 5 5 0.251 40
0 vs. 20 16702 17132 -429.9 499.3 5 5 0.861 40
0 vs. 35 16702 16984 -281.8 499.3 5 5 0.5644 40
0 vs. 100 16702 17997 -1296 499.3 5 5 2.595 40
2way ANOVA of 4B. ATP level vs. ATR-101 or PD129337 concentration
Ordinary one-way ANOVA of 4C. Cortisol secretion vs. ATR-101 concentration
Table Analyzed 4C. Cortisol secretion vs. ATR-101 concentration




P value summary ****
Significant diff. among means (P < 0.0Yes
R square 0.9126
Brown-Forsythe test
F (DFn, DFd) 1.456 (5, 30)
P value 0.2333
P value summary ns
Are SDs significantly different (P < 0.0No
Bartlett's test
Bartlett's statistic (corrected) 7.844
P value 0.1651
P value summary ns
Are SDs significantly different (P < 0.0No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 106057 5 21211 F (5, 30) = 62.64 P<0.0001
Residual (within columns) 10158 30 338.6
Total 116215 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 1 -17.99 -46.22 to 10.24 No ns 0.3262 B 1
0 vs. 10 -12.99 -41.22 to 15.24 No ns 0.6223 C 10
0 vs. 20 50.13 21.91 to 78.36 Yes *** 0.0003 D 20
0 vs. 35 104.1 75.91 to 132.4 Yes **** 0.0001 E 35
0 vs. 100 115.4 87.2 to 143.7 Yes **** 0.0001 F 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 172.4 190.4 -17.99 10.62 6 6 1.693 30
0 vs. 10 172.4 185.4 -12.99 10.62 6 6 1.223 30
0 vs. 20 172.4 122.3 50.13 10.62 6 6 4.719 30
0 vs. 35 172.4 68.25 104.1 10.62 6 6 9.802 30
0 vs. 100 172.4 56.96 115.4 10.62 6 6 10.86 30
Table Analyzed 4C. Coritsol secretion vs. ATR-101 concentration + cholesterol




P value summary ****
Significant diff. among means (P < 0.0Yes
R square 0.9459
Brown-Forsythe test
F (DFn, DFd) 1.098 (5, 30)
P value 0.382
P value summary ns
Are SDs significantly different (P < 0.0No
Ordinary one-way ANOVA of 4C. Coritsol secretion vs. ATR-101 concentration + cho
Bartlett's test
Bartlett's statistic (corrected) 12.92
P value 0.0241
P value summary *
Are SDs significantly different (P < 0.0Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 144699 5 28940 F (5, 30) = 104.9 P<0.0001
Residual (within columns) 8274 30 275.8
Total 152973 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 1 -74.09 -99.57 to -48.62 Yes **** 0.0001 B 1
0 vs. 10 -34.69 -60.17 to -9.213 Yes ** 0.0048 C 10
0 vs. 20 11.13 -14.34 to 36.61 No ns 0.6655 D 20
0 vs. 35 86.63 61.15 to 112.1 Yes **** 0.0001 E 35
0 vs. 100 106.3 80.87 to 131.8 Yes **** 0.0001 F 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 182.2 256.3 -74.09 9.588 6 6 7.727 30
0 vs. 10 182.2 216.9 -34.69 9.588 6 6 3.618 30
0 vs. 20 182.2 171.1 11.13 9.588 6 6 1.161 30
0 vs. 35 182.2 95.59 86.63 9.588 6 6 9.035 30
0 vs. 100 182.2 75.87 106.3 9.588 6 6 11.09 30
Table Analyzed 4C. Cortisol secretion vs. ATR-101 concentration + a-tocopherol




P value summary ****
Significant diff. among means (P < 0.0Yes
R square 0.8325
Brown-Forsythe test
F (DFn, DFd) 0.7591 (5, 30)
P value 0.5863
P value summary ns
Are SDs significantly different (P < 0.0No
Bartlett's test
Bartlett's statistic (corrected) 7.413
P value 0.1917
P value summary ns
Are SDs significantly different (P < 0.0No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 49720 5 9944 F (5, 30) = 29.83 P<0.0001
Residual (within columns) 10001 30 333.4
Total 59721 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Ordinary one-way ANOVA of 4C. Cortisol secretion vs. ATR-101 concentration + a-t
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 1 -26.58 -54.59 to 1.432 No ns 0.0675 B 1
0 vs. 10 -15.26 -43.27 to 12.74 No ns 0.4697 C 10
0 vs. 20 -9.219 -37.23 to 18.79 No ns 0.8497 D 20
0 vs. 35 47.54 19.53 to 75.55 Yes *** 0.0005 E 35
0 vs. 100 76.79 48.78 to 104.8 Yes **** 0.0001 F 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 185.3 211.8 -26.58 10.54 6 6 2.521 30
0 vs. 10 185.3 200.5 -15.26 10.54 6 6 1.448 30
0 vs. 20 185.3 194.5 -9.219 10.54 6 6 0.8745 30
0 vs. 35 185.3 137.7 47.54 10.54 6 6 4.51 30
0 vs. 100 185.3 108.5 76.79 10.54 6 6 7.285 30
Table Analyzed 4C ATP level vs. ATR-101 concentration




P value summary ****
Significant diff. among means (P < 0.0Yes
R square 0.9763
Brown-Forsythe test
F (DFn, DFd) 0.7001 (5, 30)
P value 0.6276
P value summary ns
Are SDs significantly different (P < 0.0No
Bartlett's test
Bartlett's statistic (corrected) 10.45
P value 0.0635
P value summary ns
Are SDs significantly different (P < 0.0No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 550462132 5 110092426 F (5, 30) = 247.1 P<0.0001
Residual (within columns) 13364823 30 445494
Total 563826955 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 1 -385.6 -1409 to 638.3 No ns 0.7739 B 1
0 vs. 10 -259.2 -1283 to 764.7 No ns 0.9403 C 10
0 vs. 20 426.5 -597.4 to 1450 No ns 0.703 D 20
0 vs. 35 3963 2939 to 4987 Yes **** 0.0001 E 35
0 vs. 100 10451 9427 to 11475 Yes **** 0.0001 F 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 13171 13557 -385.6 385.4 6 6 1.001 30
0 vs. 10 13171 13430 -259.2 385.4 6 6 0.6725 30
Ordinary one-way ANOVA of 4C ATP level vs. ATR-101 concentration
0 vs. 20 13171 12745 426.5 385.4 6 6 1.107 30
0 vs. 35 13171 9208 3963 385.4 6 6 10.28 30
0 vs. 100 13171 2720 10451 385.4 6 6 27.12 30
Table Analyzed 4C. ATP level vs. ATR-101 concentration + cholesterol




P value summary ****
Significant diff. among means (P < 0.0Yes
R square 0.6982
Brown-Forsythe test
F (DFn, DFd) 0.3485 (5, 30)
P value 0.8791
P value summary ns
Are SDs significantly different (P < 0.0No
Bartlett's test
Bartlett's statistic (corrected) 2.37
P value 0.7959
P value summary ns
Are SDs significantly different (P < 0.0No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 36638761 5 7327752 F (5, 30) = 13.88 P<0.0001
Residual (within columns) 15837206 30 527907
Total 52475967 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 1 -176.6 -1291 to 938 No ns 0.9918 B 1
0 vs. 10 647.5 -467.1 to 1762 No ns 0.4102 C 10
0 vs. 20 1607 492.2 to 2721 Yes ** 0.0028 D 20
0 vs. 35 1574 459.6 to 2689 Yes ** 0.0033 E 35
0 vs. 100 2709 1595 to 3824 Yes **** 0.0001 F 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 13724 13901 -176.6 419.5 6 6 0.421 30
0 vs. 10 13724 13077 647.5 419.5 6 6 1.543 30
0 vs. 20 13724 12117 1607 419.5 6 6 3.83 30
0 vs. 35 13724 12150 1574 419.5 6 6 3.753 30
0 vs. 100 13724 11015 2709 419.5 6 6 6.459 30
Table Analyzed 4C. ATP levels vs. ATR-101 concentration + a-tocopherol




P value summary ****
Significant diff. among means (P < 0.0Yes
R square 0.6218
Ordinary one-way ANOVA of 4C. ATP levels vs. ATR-101 concentration + a-tocophero
Ordinary one-way ANOVA of 4C. ATP level vs. ATR-101 concentration + cholesterol
Brown-Forsythe test
F (DFn, DFd) 0.2083 (5, 30)
P value 0.9564
P value summary ns
Are SDs significantly different (P < 0.0No
Bartlett's test
Bartlett's statistic (corrected) 1.838
P value 0.8711
P value summary ns
Are SDs significantly different (P < 0.0No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 28627428 5 5725486 F (5, 30) = 9.863 P<0.0001
Residual (within columns) 17414447 30 580482
Total 46041875 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 1 57.76 -1111 to 1227 No ns 0.9998 B 1
0 vs. 10 -620.7 -1789 to 548.1 No ns 0.4938 C 10
0 vs. 20 -691.7 -1860 to 477 No ns 0.393 D 20
0 vs. 35 -164.7 -1333 to 1004 No ns 0.995 E 35
0 vs. 100 1982 813.7 to 3151 Yes *** 0.0005 F 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 13602 13544 57.76 439.9 6 6 0.1313 30
0 vs. 10 13602 14223 -620.7 439.9 6 6 1.411 30
0 vs. 20 13602 14294 -691.7 439.9 6 6 1.573 30
0 vs. 35 13602 13767 -164.7 439.9 6 6 0.3744 30
0 vs. 100 13602 11620 1982 439.9 6 6 4.507 30
Table Analyzed 5A. ATP level vs. inhibitor combination




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9182
Brown-Forsythe test
F (DFn, DFd) 1.202 (7, 40)
P value 0.3242
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 20.65
P value 0.0043
P value summary **
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 524547076 7 74935297 F (7, 40) = 64.15 P<0.0001
Residual (within columns) 46724343 40 1168109
Total 571271419 47
Data summary
Number of treatments (columns) 8
Number of values (total) 48
Number of families 1
Number of comparisons per family 7
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
DMSO vs. GBZ 4604 2900 to 6309 Yes **** 0.0001 B GBZ
DMSO vs. GBZP 5865 4160 to 7569 Yes **** 0.0001 C GBZP
DMSO vs. b+GBZP -1625 -3330 to 78.78 No ns 0.067 D b+GBZP
DMSO vs. GBP -608.8 -2313 to 1095 No ns 0.8685 E GBP
DMSO vs. GZP 806.7 -897.4 to 2511 No ns 0.6628 F GZP
DMSO vs. BZP 787.4 -916.8 to 2492 No ns 0.685 G BZP
DMSO vs. ATR-101 8278 6574 to 9983 Yes **** 0.0001 H ATR-101
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
DMSO vs. GBZ 13282 8677 4604 624 6 6 7.379 40
DMSO vs. GBZP 13282 7417 5865 624 6 6 9.398 40
DMSO vs. b+GBZP 13282 14907 -1625 624 6 6 2.605 40
DMSO vs. GBP 13282 13890 -608.8 624 6 6 0.9756 40
DMSO vs. GZP 13282 12475 806.7 624 6 6 1.293 40
DMSO vs. BZP 13282 12494 787.4 624 6 6 1.262 40
DMSO vs. ATR-101 13282 5003 8278 624 6 6 13.27 40
Table Analyzed 5A. Caspase activity vs. inhibitor combination




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.8687
Ordinary one-way ANOVA of 5A. Caspase activity vs. inhibitor combination
Ordinary one-way ANOVA of 5A. ATP level vs. inhibitor combination
Brown-Forsythe test
F (DFn, DFd) 1.88 (7, 40)
P value 0.0986
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 16.98
P value 0.0175
P value summary *
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 7413299 7 1059043 F (7, 40) = 37.81 P<0.0001
Residual (within columns) 1120390 40 28010
Total 8533689 47
Data summary
Number of treatments (columns) 8
Number of values (total) 48
Number of families 1
Number of comparisons per family 7
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
DMSO vs. GBZ -932.2 -1196 to -668.3 Yes **** 0.0001 B GBZ
DMSO vs. GBZP -770.9 -1035 to -507 Yes **** 0.0001 C GBZP
DMSO vs. b+GBZP 34.5 -229.4 to 298.4 No ns 0.9994 D b+GBZP
DMSO vs. GBP 97.52 -166.4 to 361.4 No ns 0.8501 E GBP
DMSO vs. GZP -115.7 -379.6 to 148.2 No ns 0.7304 F GZP
DMSO vs. BZP -280.1 -544 to -16.25 Yes * 0.0334 G BZP
DMSO vs. ATR-101 -785.2 -1049 to -521.3 Yes **** 0.0001 H ATR-101
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
DMSO vs. GBZ 2441 3374 -932.2 96.63 6 6 9.647 40
DMSO vs. GBZP 2441 3212 -770.9 96.63 6 6 7.978 40
DMSO vs. b+GBZP 2441 2407 34.5 96.63 6 6 0.3571 40
DMSO vs. GBP 2441 2344 97.52 96.63 6 6 1.009 40
DMSO vs. GZP 2441 2557 -115.7 96.63 6 6 1.197 40
DMSO vs. BZP 2441 2722 -280.1 96.63 6 6 2.899 40
DMSO vs. ATR-101 2441 3227 -785.2 96.63 6 6 8.126 40
Table Analyzed 5C. ATP level vs. glibenclamide + DMSO




P value summary ***
Significant diff. among means (P < 0.05)? Yes
R square 0.5311
Brown-Forsythe test
F (DFn, DFd) 0.0983 (4, 25)
P value 0.982
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.1022
P value 0.9987
P value summary ns
Are SDs significantly different (P < 0.05)? No
Ordinary one-way ANOVA of 5C. ATP level vs. glibenclamide + DMSO
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 33254311 4 8313578 F (4, 25) = 7.079 P=0.0006
Residual (within columns) 29359980 25 1174399
Total 62614291 29
Data summary
Number of treatments (columns) 5
Number of values (total) 30
Number of families 1
Number of comparisons per family 4
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 50 562.2 -1069 to 2193 No ns 0.7802 B 50
0 vs. 100 1184 -446.8 to 2816 No ns 0.2051 C 100
0 vs. 250 2010 378.5 to 3641 Yes * 0.0126 D 250
0 vs. 600 2974 1343 to 4605 Yes *** 0.0003 E 600
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 50 12597 12035 562.2 625.7 6 6 0.8986 25
0 vs. 100 12597 11412 1184 625.7 6 6 1.893 25
0 vs. 250 12597 10587 2010 625.7 6 6 3.212 25
0 vs. 600 12597 9623 2974 625.7 6 6 4.753 25
Table Analyzed 5C. ATP level vs. glibenclamide + ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.8311
Brown-Forsythe test
F (DFn, DFd) 0.1577 (4, 25)
P value 0.9576
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.3589
P value 0.9857
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 143789123 4 35947281 F (4, 25) = 30.76 P<0.0001
Residual (within columns) 29215482 25 1168619
Total 173004606 29
Data summary
Number of treatments (columns) 5
Number of values (total) 30
Number of families 1
Number of comparisons per family 4
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 50 140.3 -1487 to 1768 No ns 0.998 B 50
0 vs. 100 1270 -357.2 to 2897 No ns 0.1586 C 100
0 vs. 250 1798 171.2 to 3426 Yes * 0.0272 D 250
Ordinary one-way ANOVA of 5C. ATP level vs. glibenclamide + ATR-101
0 vs. 600 6007 4380 to 7634 Yes **** 0.0001 E 600
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 50 12186 12046 140.3 624.1 6 6 0.2248 25
0 vs. 100 12186 10916 1270 624.1 6 6 2.035 25
0 vs. 250 12186 10388 1798 624.1 6 6 2.881 25
0 vs. 600 12186 6179 6007 624.1 6 6 9.625 25
Table Analyzed 5C. ATP level vs. benzamil + DMSO




P value summary ns
Significant diff. among means (P < 0.05)? No
R square 0.05655
Brown-Forsythe test
F (DFn, DFd) 0.1157 (5, 30)
P value 0.988
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.2096
P value 0.999
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 2331827 5 466365 F (5, 30) = 0.3596 P=0.8719
Residual (within columns) 38902061 30 1296735
Total 41233888 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 1 -293 -2040 to 1454 No ns 0.9892 B 1
0 vs. 2 -526.6 -2273 to 1220 No ns 0.8877 C 2
0 vs. 4 -567.4 -2314 to 1179 No ns 0.856 D 4
0 vs. 7 -386.3 -2133 to 1361 No ns 0.9649 E 7
0 vs. 10 -823.6 -2570 to 923.2 No ns 0.6015 F 10
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 12838 13131 -293 657.5 6 6 0.4457 30
0 vs. 2 12838 13364 -526.6 657.5 6 6 0.8009 30
0 vs. 4 12838 13405 -567.4 657.5 6 6 0.863 30
0 vs. 7 12838 13224 -386.3 657.5 6 6 0.5875 30
0 vs. 10 12838 13661 -823.6 657.5 6 6 1.253 30
Table Analyzed 5C. ATP level vs. benzamil + ATR-101
Data sets analyzed A : 0 B : 1 C : 2 D : 4 E : 7
ANOVA summary
Ordinary one-way ANOVA of 5C. ATP level vs. benzamil + ATR-101
Ordinary one-way ANOVA of 5C. ATP level vs. benzamil + DMSO
F 172.8
P value <0.0001
P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9664
Brown-Forsythe test
F (DFn, DFd) 0.5589 (5, 30)
P value 0.7305
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 11.97
P value 0.0351
P value summary *
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 918620466 5 183724093 F (5, 30) = 172.8 P<0.0001
Residual (within columns) 31893816 30 1063127
Total 950514283 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 1 1799 217.2 to 3381 Yes * 0.0214 B 1
0 vs. 2 2768 1186 to 4350 Yes *** 0.0003 C 2
0 vs. 4 10545 8963 to 12127 Yes **** 0.0001 D 4
0 vs. 7 11699 10117 to 13280 Yes **** 0.0001 E 7
0 vs. 10 12107 10525 to 13689 Yes **** 0.0001 F 10
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 12602 10803 1799 595.3 6 6 3.022 30
0 vs. 2 12602 9834 2768 595.3 6 6 4.65 30
0 vs. 4 12602 2057 10545 595.3 6 6 17.71 30
0 vs. 7 12602 903.5 11699 595.3 6 6 19.65 30
0 vs. 10 12602 495.1 12107 595.3 6 6 20.34 30
Table Analyzed 5C. ATP level vs. cyclosporin A + DMSO




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.709
Brown-Forsythe test
F (DFn, DFd) 0.1029 (5, 30)
P value 0.9908
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.5389
P value 0.9906
P value summary ns
Ordinary one-way ANOVA of 5C. ATP level vs. cyclosporin A + DMSO
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 74234433 5 14846887 F (5, 30) = 14.62 P<0.0001
Residual (within columns) 30470366 30 1015679
Total 104704798 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 1 150.5 -1395 to 1697 No ns 0.9987 B 1
0 vs. 2 177.1 -1369 to 1723 No ns 0.9981 C 2
0 vs. 5 530.8 -1015 to 2077 No ns 0.8282 D 5
0 vs. 10 599.3 -946.7 to 2145 No ns 0.7547 E 10
0 vs. 20 4102 2556 to 5648 Yes **** 0.0001 F 20
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 13409 13259 150.5 581.9 6 6 0.2587 30
0 vs. 2 13409 13232 177.1 581.9 6 6 0.3043 30
0 vs. 5 13409 12878 530.8 581.9 6 6 0.9123 30
0 vs. 10 13409 12810 599.3 581.9 6 6 1.03 30
0 vs. 20 13409 9307 4102 581.9 6 6 7.051 30
Table Analyzed 5C. ATP level vs. cyclosporin A + ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9505
Brown-Forsythe test
F (DFn, DFd) 0.564 (5, 30)
P value 0.7267
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 4.182
P value 0.5235
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 723545651 5 144709130 F (5, 30) = 115.2 P<0.0001
Residual (within columns) 37691953 30 1256398
Total 761237604 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
Ordinary one-way ANOVA of 5C. ATP level vs. cyclosporin A + ATR-101
0 vs. 1 -412 -2131 to 1307 No ns 0.9517 B 1
0 vs. 2 517.1 -1202 to 2237 No ns 0.8886 C 2
0 vs. 5 7192 5473 to 8912 Yes **** 0.0001 D 5
0 vs. 10 9610 7891 to 11330 Yes **** 0.0001 E 10
0 vs. 20 9697 7978 to 11417 Yes **** 0.0001 F 20
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 12346 12758 -412 647.1 6 6 0.6366 30
0 vs. 2 12346 11829 517.1 647.1 6 6 0.7991 30
0 vs. 5 12346 5154 7192 647.1 6 6 11.11 30
0 vs. 10 12346 2736 9610 647.1 6 6 14.85 30
0 vs. 20 12346 2649 9697 647.1 6 6 14.98 30
Table Analyzed 5C. ATP level vs. rhodamine 123 + DMSO




P value summary ns
Significant diff. among means (P < 0.05)? No
R square 0.1141
Brown-Forsythe test
F (DFn, DFd) 0.1034 (5, 30)
P value 0.9907
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.5004
P value 0.9921
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 3882871 5 776574 F (5, 30) = 0.7731 P=0.5767
Residual (within columns) 30136736 30 1004558
Total 34019608 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 2.5 115.3 -1422 to 1653 No ns 0.9997 B 2.5
0 vs. 5 -78.45 -1616 to 1459 No ns 0.9998 C 5
0 vs. 10 -79.82 -1617 to 1458 No ns 0.9998 D 10
0 vs. 20 316.9 -1221 to 1854 No ns 0.9737 E 20
0 vs. 50 856.7 -680.8 to 2394 No ns 0.449 F 50
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 2.5 11728 11613 115.3 578.7 6 6 0.1992 30
0 vs. 5 11728 11806 -78.45 578.7 6 6 0.1356 30
0 vs. 10 11728 11808 -79.82 578.7 6 6 0.1379 30
0 vs. 20 11728 11411 316.9 578.7 6 6 0.5476 30
0 vs. 50 11728 10871 856.7 578.7 6 6 1.48 30
Ordinary one-way ANOVA of 5C. ATP level vs. rhodamine 123 + DMSO
Table Analyzed 5C. ATP level vs. rhodamine 123 + ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9729
Brown-Forsythe test
F (DFn, DFd) 4.027 (5, 30)
P value 0.0065
P value summary **
Are SDs significantly different (P < 0.05)? Yes
Bartlett's test
Bartlett's statistic (corrected) 46.34
P value <0.0001
P value summary ****
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 585286204 5 117057241 F (5, 30) = 215.6 P<0.0001
Residual (within columns) 16289792 30 542993
Total 601575996 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 2.5 4569 3439 to 5700 Yes **** 0.0001 B 2.5
0 vs. 5 8748 7618 to 9879 Yes **** 0.0001 C 5
0 vs. 10 10577 9447 to 11708 Yes **** 0.0001 D 10
0 vs. 20 10791 9660 to 11921 Yes **** 0.0001 E 20
0 vs. 50 10800 9670 to 11930 Yes **** 0.0001 F 50
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 2.5 11004 6435 4569 425.4 6 6 10.74 30
0 vs. 5 11004 2256 8748 425.4 6 6 20.56 30
0 vs. 10 11004 426.7 10577 425.4 6 6 24.86 30
0 vs. 20 11004 213.6 10791 425.4 6 6 25.36 30
0 vs. 50 11004 204.1 10800 425.4 6 6 25.39 30
Ordinary one-way ANOVA of 5C. ATP level vs. rhodamine 123 + ATR-101
Table Analyzed 6C. ATP levels with U18666A vs. ATR-101 concentration
Two-way RM ANOVA Matching: Stacked
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 29.36 <0.0001 **** Yes
Time 25.7 <0.0001 **** Yes
Column Factor 40.9 <0.0001 **** Yes
Subjects (matching) 3.085 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 1230643094 20 61532155 F (20, 125) = 192. P<0.0001
Time 1077394297 5 215478859 F (5, 125) = 673 P<0.0001
Column Factor 1714234197 4 428558549 F (4, 25) = 82.85 P<0.0001
Subjects (matching) 129320689 25 5172828 F (25, 125) = 16.1 P<0.0001
Residual 40021689 125 320174
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 6
Number of comparisons per family 4
Alpha 0.05
Dunnett's multiple comparisons tesMean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
  0
0 vs. 5 461 -1053 to 1975 No ns 0.8667
0 vs. 10 667.6 -846.5 to 2182 No ns 0.6489
0 vs. 20 2059 544.7 to 3573 Yes ** 0.0038
0 vs. 35 2638 1123 to 4152 Yes *** 0.0001
  0.1
0 vs. 5 -72.67 -1587 to 1441 No ns 0.9998
0 vs. 10 519.1 -995 to 2033 No ns 0.8126
0 vs. 20 654.4 -859.7 to 2169 No ns 0.6643
0 vs. 35 1933 418.6 to 3447 Yes ** 0.0073
  1
0 vs. 5 258.7 -1255 to 1773 No ns 0.9808
0 vs. 10 476.8 -1037 to 1991 No ns 0.8528
0 vs. 20 523.4 -990.7 to 2038 No ns 0.8083
0 vs. 35 3432 1918 to 4946 Yes **** 0.0001
  5
0 vs. 5 29.32 -1485 to 1543 No ns 0.9999
0 vs. 10 -147.7 -1662 to 1366 No ns 0.9976
0 vs. 20 2082 568.1 to 3596 Yes ** 0.0033
0 vs. 35 12373 10859 to 13887 Yes **** 0.0001
  10
0 vs. 5 158.7 -1355 to 1673 No ns 0.9969
0 vs. 10 -402.2 -1916 to 1112 No ns 0.9125
0 vs. 20 11525 10011 to 13039 Yes **** 0.0001
0 vs. 35 12957 11443 to 14471 Yes **** 0.0001
  25
0 vs. 5 -147.2 -1661 to 1367 No ns 0.9976
0 vs. 10 4250 2735 to 5764 Yes **** 0.0001
0 vs. 20 13082 11568 to 14596 Yes **** 0.0001
0 vs. 35 12962 11448 to 14476 Yes **** 0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
  0
0 vs. 5 14865 14404 461 613.4 6 6 0.7515 150
0 vs. 10 14865 14197 667.6 613.4 6 6 1.088 150
2way ANOVA of 6C. ATP levels with U18666A vs. ATR-101 concentration
0 vs. 20 14865 12806 2059 613.4 6 6 3.356 150
0 vs. 35 14865 12227 2638 613.4 6 6 4.3 150
  0.1
0 vs. 5 14031 14104 -72.67 613.4 6 6 0.1185 150
0 vs. 10 14031 13512 519.1 613.4 6 6 0.8463 150
0 vs. 20 14031 13377 654.4 613.4 6 6 1.067 150
0 vs. 35 14031 12098 1933 613.4 6 6 3.151 150
  1
0 vs. 5 13930 13671 258.7 613.4 6 6 0.4218 150
0 vs. 10 13930 13453 476.8 613.4 6 6 0.7772 150
0 vs. 20 13930 13407 523.4 613.4 6 6 0.8532 150
0 vs. 35 13930 10498 3432 613.4 6 6 5.595 150
  5
0 vs. 5 13644 13615 29.32 613.4 6 6 0.0478 150
0 vs. 10 13644 13792 -147.7 613.4 6 6 0.2407 150
0 vs. 20 13644 11562 2082 613.4 6 6 3.394 150
0 vs. 35 13644 1272 12373 613.4 6 6 20.17 150
  10
0 vs. 5 13375 13216 158.7 613.4 6 6 0.2587 150
0 vs. 10 13375 13777 -402.2 613.4 6 6 0.6556 150
0 vs. 20 13375 1850 11525 613.4 6 6 18.79 150
0 vs. 35 13375 417.9 12957 613.4 6 6 21.12 150
  25
0 vs. 5 13461 13608 -147.2 613.4 6 6 0.24 150
0 vs. 10 13461 9211 4250 613.4 6 6 6.927 150
0 vs. 20 13461 378.6 13082 613.4 6 6 21.33 150
0 vs. 35 13461 498.5 12962 613.4 6 6 21.13 150






P value summary ****
Significantly different (P < 0.05)? Yes
One- or two-tailed P value? Two-tailed
t, df t=21.01 df=10
How big is the difference?
Mean ± SEM of column A 1925 ± 393.9, n=6
Mean ± SEM of column B 16009 ± 542.4, n=6
Difference between means 14084 ± 670.3
95% confidence interval 12590 to 15577
R squared (eta squared) 0.9778
F test to compare variances
F, DFn, Dfd 1.897, 5, 5
P value 0.4993
P value summary ns
Significantly different (P < 0.05)? No
Unpaired t test of 6D. ATP levels with ATR-101 and U18666A vs. ATR-101, U18666A, MBCD
Table Analyzed 7A. ABCA1 levels vs. ATR-101 concentration, 1 h




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.8205
Brown-Forsythe test
F (DFn, DFd) 0.08223 (3, 16)
P value 0.9687
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.08657
P value 0.9934
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 7.17E-07 3 2.39E-07 F (3, 16) = 24.37 P<0.0001
Residual (within columns) 1.569E-07 16 9.807E-09
Total 8.739E-07 19
Data summary
Number of treatments (columns) 4
Number of values (total) 20
Number of families 1
Number of comparisons per family 3
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 8 0.0004025 0.0002401 to 0.0005649 Yes **** 0.0001 B 8
0 vs. 16 0.0004713 0.0003089 to 0.0006336 Yes **** 0.0001 C 16
0 vs. 32 0.0004269 0.0002645 to 0.0005893 Yes **** 0.0001 D 32
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 8 0.001442 0.00104 0.0004025 0.00006263 5 5 6.426 16
0 vs. 16 0.001442 0.0009709 0.0004713 0.00006263 5 5 7.524 16
0 vs. 32 0.001442 0.001015 0.0004269 0.00006263 5 5 6.816 16
Table Analyzed 7A. ABCG1 levels vs. ATR-101 concentration, 1 h




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9871
Brown-Forsythe test
F (DFn, DFd) 0.4793 (3, 16)
P value 0.7012
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 1.308
P value 0.7272
P value summary ns
Are SDs significantly different (P < 0.05)? No
Ordinary one-way ANOVA of 7A. ABCA1 levels vs. ATR-101 concentration, 1 h
Ordinary one-way ANOVA of 7A. ABCG1 levels vs. ATR-101 concentration, 1 h
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 9.169E-09 3 3.056E-09 F (3, 16) = 409.6 P<0.0001
Residual (within columns) 1.194E-10 16 7.461E-12
Total 9.288E-09 19
Data summary
Number of treatments (columns) 4
Number of values (total) 20
Number of families 1
Number of comparisons per family 3
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 8 0.0000343 2.982e-005 to 3.878e-005 Yes **** 0.0001 B 8
0 vs. 16 5.636E-05 5.188e-005 to 6.084e-005 Yes **** 0.0001 C 16
0 vs. 32 4.736E-05 4.288e-005 to 5.184e-005 Yes **** 0.0001 D 32
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 8 0.000075 0.0000407 0.0000343 0.000001728 5 5 19.85 16
0 vs. 16 0.000075 0.00001864 5.636E-05 0.000001728 5 5 32.63 16
0 vs. 32 0.000075 0.00002764 4.736E-05 0.000001728 5 5 27.42 16
Table Analyzed 7A. IDOL levels vs. ATR-101 concentration, 1 h




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9143
Brown-Forsythe test
F (DFn, DFd) 3.557 (3, 16)
P value 0.0382
P value summary *
Are SDs significantly different (P < 0.05)? Yes
Bartlett's test
Bartlett's statistic (corrected) 6.567
P value 0.0871
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 6.85E-06 3 2.283E-06 F (3, 16) = 56.87 P<0.0001
Residual (within columns) 6.424E-07 16 4.015E-08
Total 7.492E-06 19
Data summary
Number of treatments (columns) 4
Number of values (total) 20
Number of families 1
Number of comparisons per family 3
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 8 0.00115 0.0008219 to 0.001479 Yes **** 0.0001 B 8
0 vs. 16 0.001487 0.001159 to 0.001816 Yes **** 0.0001 C 16
0 vs. 32 0.001332 0.001003 to 0.00166 Yes **** 0.0001 D 32
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 8 0.002498 0.001348 0.00115 0.0001267 5 5 9.078 16
0 vs. 16 0.002498 0.001011 0.001487 0.0001267 5 5 11.74 16
Ordinary one-way ANOVA of 7A. IDOL levels vs. ATR-101 concentration, 1 h
0 vs. 32 0.002498 0.001167 0.001332 0.0001267 5 5 10.51 16
Table Analyzed 7A. CHOP levels vs. ATR-101 concentration, 1 h




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.8689
Brown-Forsythe test
F (DFn, DFd) 0.1769 (3, 16)
P value 0.9105
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.1917
P value 0.9789
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 1.968E-05 3 6.561E-06 F (3, 16) = 35.36 P<0.0001
Residual (within columns) 2.969E-06 16 1.856E-07
Total 2.265E-05 19
Data summary
Number of treatments (columns) 4
Number of values (total) 20
Number of families 1
Number of comparisons per family 3
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 8 9.186E-05 -0.0006145 to 0.0007982 No ns 0.9739 B 8
0 vs. 16 0.0001666 -0.0005398 to 0.0008729 No ns 0.8734 C 16
0 vs. 32 -0.002201 -0.002907 to -0.001495 Yes **** 0.0001 D 32
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 8 0.005861 0.005769 9.186E-05 0.0002725 5 5 0.3372 16
0 vs. 16 0.005861 0.005694 0.0001666 0.0002725 5 5 0.6114 16
0 vs. 32 0.005861 0.008062 -0.002201 0.0002725 5 5 8.078 16
Table Analyzed 7B. CYP17A1 transcripts vs. ATR-101




P value summary **
Significant diff. among means (P < 0.05)? Yes
R square 0.4311
Brown-Forsythe test
F (DFn, DFd) 15.77 (2, 21)
P value <0.0001
P value summary ****
Are SDs significantly different (P < 0.05)? Yes
Bartlett's test
Bartlett's statistic (corrected) 11.22
P value 0.0037
P value summary **
Ordinary one-way ANOVA of 7A. CHOP levels vs. ATR-101 concentration, 1 h
Ordinary one-way ANOVA of 7B. CYP17A1 transcripts vs. ATR-101
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 0.03325 2 0.01662 F (2, 21) = 7.957 P=0.0027
Residual (within columns) 0.04387 21 0.002089
Total 0.07711 23
Data summary
Number of treatments (columns) 3
Number of values (total) 24
Number of families 1
Number of comparisons per family 2
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
DMSO vs. 16 0.0712 0.01703 to 0.1254 Yes ** 0.0099 B 16
DMSO vs. 32 0.08491 0.03074 to 0.1391 Yes ** 0.0024 C 32
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
DMSO vs. 16 0.2174 0.1462 0.0712 0.02285 8 8 3.116 21
DMSO vs. 32 0.2174 0.1325 0.08491 0.02285 8 8 3.715 21
Table Analyzed 7B. SULT2A1 transcripts vs. ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.6289
Brown-Forsythe test
F (DFn, DFd) 0.9893 (2, 21)
P value 0.3885
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 2.157
P value 0.3401
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 0.000072 2 0.000036 F (2, 21) = 17.79 P<0.0001
Residual (within columns) 4.249E-05 21 2.023E-06
Total 0.0001145 23
Data summary
Number of treatments (columns) 3
Number of values (total) 24
Number of families 1
Number of comparisons per family 2
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
DMSO vs. 16 0.003669 0.001983 to 0.005355 Yes **** 0.0001 B 16
DMSO vs. 32 0.003679 0.001993 to 0.005365 Yes **** 0.0001 C 32
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
DMSO vs. 16 0.008212 0.004543 0.003669 0.0007112 8 8 5.159 21
DMSO vs. 32 0.008212 0.004533 0.003679 0.0007112 8 8 5.173 21
Ordinary one-way ANOVA of 7B. SULT2A1 transcripts vs. ATR-101
Table Analyzed 7B. HSD3B2 transcripts vs. ATR-101




P value summary **
Significant diff. among means (P < 0.05)? Yes
R square 0.3698
Brown-Forsythe test
F (DFn, DFd) 18.12 (2, 21)
P value <0.0001
P value summary ****
Are SDs significantly different (P < 0.05)? Yes
Bartlett's test
Bartlett's statistic (corrected) 6.82
P value 0.033
P value summary *
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 4.246E-05 2 2.123E-05 F (2, 21) = 6.162 P=0.0078
Residual (within columns) 7.234E-05 21 3.445E-06
Total 0.0001148 23
Data summary
Number of treatments (columns) 3
Number of values (total) 24
Number of families 1
Number of comparisons per family 2
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
DMSO vs. 16 0.002954 0.0007546 to 0.005154 Yes ** 0.0085 B 16
DMSO vs. 32 0.002666 0.0004667 to 0.004866 Yes * 0.017 C 32
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
DMSO vs. 16 0.006383 0.003429 0.002954 0.000928 8 8 3.184 21
DMSO vs. 32 0.006383 0.003717 0.002666 0.000928 8 8 2.873 21
Table Analyzed 7B. CYP21A2 transcripts vs. ATR-101




P value summary *
Significant diff. among means (P < 0.05)? Yes
R square 0.2767
Brown-Forsythe test
F (DFn, DFd) 2.41 (2, 21)
P value 0.1143
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 3.569
P value 0.1679
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 0.002716 2 0.001358 F (2, 21) = 4.018 P=0.0333
Ordinary one-way ANOVA of 7B. CYP21A2 transcripts vs. ATR-101
Ordinary one-way ANOVA of 7B. HSD3B2 transcripts vs. ATR-101
Residual (within columns) 0.007097 21 0.000338
Total 0.009813 23
Data summary
Number of treatments (columns) 3
Number of values (total) 24
Number of families 1
Number of comparisons per family 2
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
DMSO vs. 16 0.01356 -0.008223 to 0.03535 No ns 0.2612 B 16
DMSO vs. 32 0.02605 0.00426 to 0.04784 Yes * 0.0186 C 32
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
DMSO vs. 16 0.09619 0.08262 0.01356 0.009192 8 8 1.476 21
DMSO vs. 32 0.09619 0.07014 0.02605 0.009192 8 8 2.834 21
Table Analyzed S1A. Mean fluorescence intensity of cell clusters vs. time after ATR-101 additio
Column B 0.25 h ATR-101
vs. vs.
Column A 0.25 h DMSO
Unpaired t test
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
One- or two-tailed P value? Two-tailed
t, df t=9.345 df=617
How big is the difference?
Mean ± SEM of column A 28.76 ± 0.5096, n=313
Mean ± SEM of column B 36.52 ± 0.6587, n=306
Difference between means 7.761 ± 0.8306
95% confidence interval 6.13 to 9.392
R squared (eta squared) 0.124
F test to compare variances
F, DFn, Dfd 1.633, 305, 312
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
Table Analyzed S1A. Mean fluorescence intensity of cell clusters vs. time after ATR-101 additio
Column D 0.5 h ATR-101
vs. vs.
Column C 0.5 h DMSO
Unpaired t test
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
One- or two-tailed P value? Two-tailed
t, df t=7.284 df=532
How big is the difference?
Mean ± SEM of column C 29.34 ± 0.4887, n=313
Mean ± SEM of column D 35.71 ± 0.777, n=221
Difference between means 6.368 ± 0.8743
95% confidence interval 4.651 to 8.085
R squared (eta squared) 0.09068
F test to compare variances
F, DFn, Dfd 1.785, 220, 312
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
Table Analyzed S1A. Mean fluorescence intensity of cell clusters vs. time after ATR-101 additio
Column F 1 h ATR-101
vs. vs.
Column E 1 h DMSO
Unpaired t test
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
One- or two-tailed P value? Two-tailed
t, df t=19.86 df=617
Unpaired t test of S1A. Mean fluorescence intensity of cell clusters vs. ATR-101 or DMSO, 0.5 h
Unpaired t test of S1A. Mean fluorescence intensity of cell clusters vs. ATR-101 or DMSO, 0.25 h
Unpaired t test of S1A. Mean fluorescence intensity of cell clusters vs. ATR-101 or DMSO, 1 h
How big is the difference?
Mean ± SEM of column E 26.29 ± 0.4407, n=306
Mean ± SEM of column F 44.54 ± 0.7997, n=313
Difference between means 18.25 ± 0.9187
95% confidence interval 16.44 to 20.05
R squared (eta squared) 0.39
F test to compare variances
F, DFn, Dfd 3.369, 312, 305
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
Table Analyzed S1A. Mean fluorescence intensity of cell clusters vs. time after ATR-101 additio
Column H 2 h ATR-101
vs. vs.
Column G 2 h DMSO
Unpaired t test
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
One- or two-tailed P value? Two-tailed
t, df t=11.94 df=567
How big is the difference?
Mean ± SEM of column G 24.93 ± 0.452, n=266
Mean ± SEM of column H 40.5 ± 1.155, n=303
Difference between means 15.57 ± 1.304
95% confidence interval 13.01 to 18.13
R squared (eta squared) 0.2009
F test to compare variances
F, DFn, Dfd 7.443, 302, 265
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
Table Analyzed S1A. Mean fluorescence intensity of cell clusters vs. time after ATR-101 additio
Column J 4 h ATR-101
vs. vs.
Column I 4 h DMSO
Unpaired t test
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
One- or two-tailed P value? Two-tailed
t, df t=33.46 df=546
How big is the difference?
Mean ± SEM of column I 20.51 ± 0.3551, n=303
Mean ± SEM of column J 54.69 ± 1.048, n=245
Difference between means 34.18 ± 1.021
95% confidence interval 32.17 to 36.19
R squared (eta squared) 0.6722
F test to compare variances
F, DFn, Dfd 7.04, 244, 302
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
Unpaired t test of S1A. Mean fluorescence intensity of cell clusters vs. ATR-101 or DMSO, 2 h
Unpaired t test of S1A. Mean fluorescence intensity of cell clusters vs. ATR-101 or DMSO, 4 h
Table Analyzed S1B. H295R ATP level vs. ATR-101 or PD129337 concentration, 24 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 29.17 <0.0001 **** Yes
Row Factor 31.81 <0.0001 **** Yes
Column Factor 35.53 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 352182736 6 58697123 F (6, 70) = 97.52 P<0.0001
Row Factor 383961538 6 63993590 F (6, 70) = 106.3 P<0.0001
Column Factor 428932710 1 428932710 F (1, 70) = 712.6 P<0.0001
Residual 42133227 70 601903
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 7
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101 - PD129337
    0 42.94 -1195 to 1281 No ns >0.9999
    5 -99.91 -1338 to 1138 No ns >0.9999
    10 -517.7 -1756 to 720.1 No ns 0.8686
    20 -4149 -5387 to -2911 Yes **** <0.0001
    40 -7999 -9237 to -6761 Yes **** <0.0001
    60 -9318 -10556 to -8080 Yes **** <0.0001
    100 -9595 -10833 to -8357 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101 - PD129337
    0 10729 10686 42.94 447.9 6 6 0.09587 70
    5 10445 10544 -99.91 447.9 6 6 0.2231 70
    10 9836 10353 -517.7 447.9 6 6 1.156 70
    20 6291 10440 -4149 447.9 6 6 9.263 70
    40 2197 10196 -7999 447.9 6 6 17.86 70
    60 1146 10464 -9318 447.9 6 6 20.8 70
    100 740.5 10336 -9595 447.9 6 6 21.42 70
Table Analyzed S1B. H295R caspase activity vs. ATR-101 or PD129337 concentration, 24 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 33.25 <0.0001 **** Yes
Row Factor 33.18 <0.0001 **** Yes
Column Factor 31.17 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 71369450 6 11894908 F (6, 70) = 162.1 P<0.0001
Row Factor 71216324 6 11869387 F (6, 70) = 161.7 P<0.0001
Column Factor 66894919 1 66894919 F (1, 70) = 911.4 P<0.0001
Residual 5137902 70 73399
Number of missing values 0
Compare each cell mean with the other cell mean in that row
2way ANOVA of S1B. H295R caspase level vs. ATR-101 or PD129337 concentration, 24
2way ANOVA of S1B. H295R ATP level vs. ATR-101 or PD129337 concentration, 24 h
Number of families 1
Number of comparisons per family 7
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101 - PD129337
    0 -6.626 -438.9 to 425.6 No ns >0.9999
    5 95.48 -336.8 to 527.7 No ns 0.9959
    10 78.62 -353.6 to 510.9 No ns 0.9988
    20 762.1 329.9 to 1194 Yes **** <0.0001
    40 3076 2644 to 3508 Yes **** <0.0001
    60 4180 3748 to 4612 Yes **** <0.0001
    100 4308 3876 to 4740 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101 - PD129337
    0 1011 1018 -6.626 156.4 6 6 0.04236 70
    5 1122 1027 95.48 156.4 6 6 0.6104 70
    10 1089 1010 78.62 156.4 6 6 0.5026 70
    20 1779 1017 762.1 156.4 6 6 4.872 70
    40 4085 1009 3076 156.4 6 6 19.67 70
    60 5200 1020 4180 156.4 6 6 26.72 70
    100 5323 1016 4308 156.4 6 6 27.54 70
Table Analyzed S1B. BD140C ATP level vs. ATR-101 or PD129337 concentration, 24 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 21.78 <0.0001 **** Yes
Row Factor 26.07 <0.0001 **** Yes
Column Factor 50.34 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 113202050 5 22640410 F (5, 60) = 144.6 P<0.0001
Row Factor 135468390 5 27093678 F (5, 60) = 173 P<0.0001
Column Factor 261609260 1 261609260 F (1, 60) = 1670 P<0.0001
Residual 9396613 60 156610
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 6
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101 - PD129337
    0 -81.91 -703.5 to 539.7 No ns 0.9995
    5 -980.3 -1602 to -358.7 Yes *** 0.0004
    10 -3584 -4205 to -2962 Yes **** <0.0001
    20 -5584 -6206 to -4963 Yes **** <0.0001
    40 -6396 -7018 to -5775 Yes **** <0.0001
    60 -6247 -6869 to -5626 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101 - PD129337
    0 6752 6834 -81.91 228.5 6 6 0.3585 60
    5 5738 6719 -980.3 228.5 6 6 4.291 60
2way ANOVA of S1B. BD140C ATP level vs. ATR-101 or PD129337 concentration, 24 h
    10 3290 6874 -3584 228.5 6 6 15.69 60
    20 1146 6731 -5584 228.5 6 6 24.44 60
    40 160.6 6557 -6396 228.5 6 6 27.99 60
    60 134.1 6381 -6247 228.5 6 6 27.34 60
Table Analyzed S1B. BD140C caspase activity vs. ATR-101 or PD129337 concentration, 24 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 28.59 <0.0001 **** Yes
Row Factor 28.42 <0.0001 **** Yes
Column Factor 41.64 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 137215815 4 34303954 F (4, 50) = 264.3 P<0.0001
Row Factor 136400350 4 34100088 F (4, 50) = 262.7 P<0.0001
Column Factor 199824692 1 199824692 F (1, 50) = 1539 P<0.0001
Residual 6490374 50 129807
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101 - PD129337
    0 7.624 -547.8 to 563 No ns >0.9999
    5 771.3 215.9 to 1327 Yes ** 0.0026
    10 3240 2685 to 3796 Yes **** <0.0001
    20 7142 6587 to 7698 Yes **** <0.0001
    40 7088 6533 to 7643 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
ATR-101 - PD129337
    0 1014 1006 7.624 208 6 6 0.03665 50
    5 1791 1020 771.3 208 6 6 3.708 50
    10 4254 1014 3240 208 6 6 15.58 50
    20 8148 1006 7142 208 6 6 34.34 50
    40 8087 999.3 7088 208 6 6 34.07 50
2way ANOVA of S1B. BD140C caspase activity vs. ATR-101 or PD129337 concentration
Table Analyzed S2B. ATP level vs. MBCD concentration, 24 h, +ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9718
Brown-Forsythe test
F (DFn, DFd) 4.438 (5, 30)
P value 0.0038
P value summary **
Are SDs significantly different (P < 0.05)? Yes
Bartlett's test
Bartlett's statistic (corrected) 28.63
P value <0.0001
P value summary ****
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 3045702518 5 609140504 F (5, 30) = 206.9 P<0.0001
Residual (within columns) 88319546 30 2943985
Total 3134022064 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 0.25 -58.33 -2690 to 2574 No ns 0.9999 B 0.25
0 vs. 0.5 -491.5 -3124 to 2141 No ns 0.9826 C 0.5
0 vs. 1 -13348 -15980 to -10716 Yes **** 0.0001 D 1
0 vs. 1.5 -19748 -22380 to -17116 Yes **** 0.0001 E 1.5
0 vs. 2 -20827 -23459 to -18195 Yes **** 0.0001 F 2
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 0.25 565.7 624 -58.33 990.6 6 6 0.05888 30
0 vs. 0.5 565.7 1057 -491.5 990.6 6 6 0.4961 30
0 vs. 1 565.7 13914 -13348 990.6 6 6 13.47 30
0 vs. 1.5 565.7 20314 -19748 990.6 6 6 19.94 30
0 vs. 2 565.7 21393 -20827 990.6 6 6 21.02 30
Table Analyzed S2B. Caspase activity vs. MBCD concentration, 24 h, +ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9718
Brown-Forsythe test
F (DFn, DFd) 4.438 (5, 30)
P value 0.0038
P value summary **
Are SDs significantly different (P < 0.05)? Yes
Bartlett's test
Bartlett's statistic (corrected) 28.63
P value <0.0001
Ordinary one-way ANOVA of S2B. Caspase activity vs. MBCD concentration, 24 h, +A
Ordinary one-way ANOVA of S2B. ATP level vs. MBCD concentration, 24 h, +ATR-101
P value summary ****
Are SDs significantly different (P < 0.05)? Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 3045702518 5 609140504 F (5, 30) = 206.9 P<0.0001
Residual (within columns) 88319546 30 2943985
Total 3134022064 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 0.25 -58.33 -2690 to 2574 No ns 0.9999 B 0.25
0 vs. 0.5 -491.5 -3124 to 2141 No ns 0.9826 C 0.5
0 vs. 1 -13348 -15980 to -10716 Yes **** 0.0001 D 1
0 vs. 1.5 -19748 -22380 to -17116 Yes **** 0.0001 E 1.5
0 vs. 2 -20827 -23459 to -18195 Yes **** 0.0001 F 2
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 0.25 565.7 624 -58.33 990.6 6 6 0.05888 30
0 vs. 0.5 565.7 1057 -491.5 990.6 6 6 0.4961 30
0 vs. 1 565.7 13914 -13348 990.6 6 6 13.47 30
0 vs. 1.5 565.7 20314 -19748 990.6 6 6 19.94 30
0 vs. 2 565.7 21393 -20827 990.6 6 6 21.02 30
Table Analyzed S2C. ATP level vs. cholesterol concentration, 4 h, +ATR-101




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.609
Brown-Forsythe test
F (DFn, DFd) 0.3888 (5, 30)
P value 0.8525
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 1.162
P value 0.9485
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 56133808 5 11226762 F (5, 30) = 9.344 P<0.0001
Residual (within columns) 36045535 30 1201518
Total 92179343 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 1 -1011 -2693 to 670.4 No ns 0.3784 B 1
0 vs. 2.5 -1863 -3545 to -181.8 Yes * 0.0258 C 2.5
0 vs. 5 -2079 -3760 to -397.2 Yes * 0.0112 D 5
Ordinary one-way ANOVA of S2C. ATP level vs. cholesterol concentration, 4 h, +AT
0 vs. 10 -2904 -4586 to -1223 Yes *** 0.0004 E 10
0 vs. 25 -3883 -5565 to -2202 Yes **** 0.0001 F 25
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 1 4228 5239 -1011 632.9 6 6 1.598 30
0 vs. 2.5 4228 6091 -1863 632.9 6 6 2.944 30
0 vs. 5 4228 6306 -2079 632.9 6 6 3.285 30
0 vs. 10 4228 7132 -2904 632.9 6 6 4.589 30
0 vs. 25 4228 8111 -3883 632.9 6 6 6.136 30
Table Analyzed S2C. Caspase activity vs. cholesterol concentration, 4 h, + ATR-101




P value summary ns
Significant diff. among means (P < 0.05)? No
R square 0.2299
Brown-Forsythe test
F (DFn, DFd) 0.747 (5, 30)
P value 0.5947
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 6.699
P value 0.244
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 864853 5 172971 F (5, 30) = 1.791 P=0.1450
Residual (within columns) 2897696 30 96590
Total 3762548 35
Data summary
Number of treatments (columns) 6
Number of values (total) 36
Number of families 1
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value A-?
0 vs. 2.5 29.63 -447.1 to 506.4 No ns 0.9997 B 2.5
0 vs. 10 151.7 -325.1 to 628.4 No ns 0.8654 C 10
0 vs. 25 226.1 -250.7 to 702.8 No ns 0.5964 D 25
0 vs. 50 -4.281 -481 to 472.5 No ns 0.9999 E 50
0 vs. 100 -268.6 -745.3 to 208.2 No ns 0.4387 F 100
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 2.5 2482 2453 29.63 179.4 6 6 0.1651 30
0 vs. 10 2482 2331 151.7 179.4 6 6 0.8453 30
0 vs. 25 2482 2256 226.1 179.4 6 6 1.26 30
0 vs. 50 2482 2487 -4.281 179.4 6 6 0.02386 30
0 vs. 100 2482 2751 -268.6 179.4 6 6 1.497 30
Table Analyzed S2D. ATP level vs. cholesterol or cholesterol linoleate concentration




Unpaired t test of S2D. ATP level vs. cholesterol or cholesterol linoleate conce
Ordinary one-way ANOVA of S2C. Caspase activity vs. cholesterol concentration, 4
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
One- or two-tailed P value? Two-tailed
t, df t=7.167 df=22
How big is the difference?
Mean ± SEM of column A 5574 ± 753.1, n=12
Mean ± SEM of column B 173.3 ± 27.08, n=12
Difference between means -5401 ± 753.6
95% confidence interval -6964 to -3838
R squared (eta squared) 0.7002
F test to compare variances
F, DFn, Dfd 773.2, 11, 11
P value <0.0001
P value summary ****
Significantly different (P < 0.05)? Yes
Table Analyzed S2F. Resazurin reducing potential vs. time, +ATR-101 or DMSO
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 5.571 <0.0001 **** Yes
Row Factor 68.82 <0.0001 **** Yes
Column Factor 23.54 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 2695702 6 449284 F (6, 70) = 31.45 P<0.0001
Row Factor 33297777 6 5549630 F (6, 70) = 388.5 P<0.0001
Column Factor 11392473 1 11392473 F (1, 70) = 797.4 P<0.0001
Residual 1000056 70 14287
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 7
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO - ATR-101
    0 0 -190.7 to 190.7 No ns >0.9999
    73 -536.5 -727.2 to -345.8 Yes **** <0.0001
    126 -665.8 -856.5 to -475.1 Yes **** <0.0001
    215 -819.9 -1011 to -629.2 Yes **** <0.0001
    250 -930.6 -1121 to -739.9 Yes **** <0.0001
    314 -1098 -1288 to -906.9 Yes **** <0.0001
    362 -1105 -1296 to -914.7 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO - ATR-101
    0 0 0 0 69.01 6 6 0 70
    73 261.8 798.3 -536.5 69.01 6 6 7.774 70
    126 516.8 1183 -665.8 69.01 6 6 9.648 70
    215 597.5 1417 -819.9 69.01 6 6 11.88 70
    250 798.2 1729 -930.6 69.01 6 6 13.49 70
    314 1198 2296 -1098 69.01 6 6 15.9 70
    362 1408 2513 -1105 69.01 6 6 16.02 70
Table Analyzed S2F. Resazurin reducing potential vs. time, +ATR-101 or DMSO
Two-way ANOVA Ordinary
Alpha 0.05
2way ANOVA of S2F. Resazurin reducing potential vs. time, +ATR-101 or DMSO
2way ANOVA of S2F. Resazurin reducing potential vs. time, +ATR-101 DMSO, +MBCD
Source of Variation % of total variation P value P value summary Significant?
Interaction 5.813 <0.0001 **** Yes
Row Factor 69.19 <0.0001 **** Yes
Column Factor 22.28 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 4390725 6 731788 F (6, 70) = 24.99 P<0.0001
Row Factor 52260277 6 8710046 F (6, 70) = 297.5 P<0.0001
Column Factor 16831709 1 16831709 F (1, 70) = 574.8 P<0.0001
Residual 2049679 70 29281
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 7
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
MBCD+DMSO - MBCD+ATR-101
    0 0 -273 to 273 No ns >0.9999
    73 -715.9 -988.9 to -442.9 Yes **** <0.0001
    126 -794.8 -1068 to -521.8 Yes **** <0.0001
    215 -920.9 -1194 to -647.9 Yes **** <0.0001
    250 -969 -1242 to -696 Yes **** <0.0001
    314 -1301 -1574 to -1028 Yes **** <0.0001
    362 -1566 -1839 to -1293 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
MBCD+DMSO - MBCD+ATR-101
    0 0 0 0 98.79 6 6 0 70
    73 357.9 1074 -715.9 98.79 6 6 7.246 70
    126 742.7 1537 -794.8 98.79 6 6 8.045 70
    215 779.2 1700 -920.9 98.79 6 6 9.322 70
    250 1033 2002 -969 98.79 6 6 9.809 70
    314 1427 2728 -1301 98.79 6 6 13.16 70
    362 1800 3366 -1566 98.79 6 6 15.85 70
Table Analyzed S2I. ATP level vs. cholesterol:MBCD concentration, 4 h, +ATR-101
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 12.76 <0.0001 **** Yes
Row Factor 71.63 <0.0001 **** Yes
Column Factor 4.485 0.0009 *** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 140406209 5 28081242 F (5, 60) = 13.77 P<0.0001
Row Factor 787951020 1 787951020 F (1, 60) = 386.5 P<0.0001
Column Factor 49333479 5 9866696 F (5, 60) = 4.839 P=0.0009
Residual 122328663 60 2038811
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 2
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO
0 vs. 0.25 -1069 -3198 to 1060 No ns 0.5659
0 vs. 0.5 -760.6 -2890 to 1368 No ns 0.8228
0 vs. 1 1615 -513.9 to 3744 No ns 0.1954
0 vs. 1.5 1665 -463.8 to 3794 No ns 0.1734
2way ANOVA of S2I. ATP level vs. cholesterol:MBCD concentration, 4 h, +ATR-101
0 vs. 2 2149 20.03 to 4278 Yes * 0.0471
ATR-101
0 vs. 0.25 -3297 -5426 to -1168 Yes *** 0.0008
0 vs. 0.5 -4525 -6654 to -2396 Yes **** 0.0001
0 vs. 1 -4474 -6603 to -2345 Yes **** 0.0001
0 vs. 1.5 -5336 -7465 to -3207 Yes **** 0.0001
0 vs. 2 -5825 -7954 to -3696 Yes **** 0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
DMSO
0 vs. 0.25 19555 20625 -1069 824.4 6 6 1.297 60
0 vs. 0.5 19555 20316 -760.6 824.4 6 6 0.9226 60
0 vs. 1 19555 17940 1615 824.4 6 6 1.959 60
0 vs. 1.5 19555 17890 1665 824.4 6 6 2.02 60
0 vs. 2 19555 17406 2149 824.4 6 6 2.607 60
ATR-101
0 vs. 0.25 8429 11727 -3297 824.4 6 6 4 60
0 vs. 0.5 8429 12955 -4525 824.4 6 6 5.489 60
0 vs. 1 8429 12903 -4474 824.4 6 6 5.427 60
0 vs. 1.5 8429 13765 -5336 824.4 6 6 6.472 60
0 vs. 2 8429 14255 -5825 824.4 6 6 7.066 60
Table Analyzed S2I. Caspase activity vs. cholesterol:MBCD concentration, 4 h, +ATR-101
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 3.473 <0.0001 **** Yes
Row Factor 5.602 <0.0001 **** Yes
Column Factor 86.17 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 513047069 5 102609414 F (5, 60) = 8.766 P<0.0001
Row Factor 827529992 1 827529992 F (1, 60) = 70.7 P<0.0001
Column Factor 12729423881 5 2545884776 F (5, 60) = 217.5 P<0.0001
Residual 702290283 60 11704838
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 2
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO
0 vs. 0.25 -108.7 -5210 to 4993 No ns 0.9999
0 vs. 0.5 -1326 -6427 to 3775 No ns 0.9419
0 vs. 1 -19084 -24186 to -13983 Yes **** 0.0001
0 vs. 1.5 -25911 -31012 to -20809 Yes **** 0.0001
0 vs. 2 -29244 -34345 to -24142 Yes **** 0.0001
ATR-101
0 vs. 0.25 -97.8 -5199 to 5004 No ns 0.9999
0 vs. 0.5 -10919 -16021 to -5818 Yes **** 0.0001
0 vs. 1 -33389 -38490 to -28288 Yes **** 0.0001
0 vs. 1.5 -31364 -36466 to -26263 Yes **** 0.0001
0 vs. 2 -30623 -35724 to -25521 Yes **** 0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
DMSO
0 vs. 0.25 858.7 967.4 -108.7 1975 6 6 0.05504 60
0 vs. 0.5 858.7 2185 -1326 1975 6 6 0.6713 60
0 vs. 1 858.7 19943 -19084 1975 6 6 9.662 60
2way ANOVA of S2I. Caspase activity vs. cholesterol:MBCD concentration, 4 h, +AT
0 vs. 1.5 858.7 26770 -25911 1975 6 6 13.12 60
0 vs. 2 858.7 30102 -29244 1975 6 6 14.81 60
ATR-101
0 vs. 0.25 2519 2617 -97.8 1975 6 6 0.04951 60
0 vs. 0.5 2519 13439 -10919 1975 6 6 5.528 60
0 vs. 1 2519 35908 -33389 1975 6 6 16.9 60
0 vs. 1.5 2519 33883 -31364 1975 6 6 15.88 60
0 vs. 2 2519 33142 -30623 1975 6 6 15.5 60
Table Analyzed S2I. ATP level vs. cholesterol:MBCD concentration, 24 h, +ATR-101
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 15.64 <0.0001 **** Yes
Row Factor 32.34 <0.0001 **** Yes
Column Factor 48.85 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 541981972 5 108396394 F (5, 60) = 59.07 P<0.0001
Row Factor 1121055969 1 1121055969 F (1, 60) = 610.9 P<0.0001
Column Factor 1693093343 5 338618669 F (5, 60) = 184.5 P<0.0001
Residual 110105886 60 1835098
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 2
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO
0 vs. 0.25 -609.4 -2629 to 1410 No ns 0.8991
0 vs. 0.5 8.708 -2011 to 2029 No ns 0.9999
0 vs. 1 11975 9955 to 13995 Yes **** 0.0001
0 vs. 1.5 14225 12205 to 16245 Yes **** 0.0001
0 vs. 2 14320 12300 to 16340 Yes **** 0.0001
ATR-101
0 vs. 0.25 -10623 -12643 to -8604 Yes **** 0.0001
0 vs. 0.5 -5010 -7029 to -2990 Yes **** 0.0001
0 vs. 1 -1781 -3801 to 238.9 No ns 0.1014
0 vs. 1.5 -227.6 -2248 to 1792 No ns 0.9983
0 vs. 2 -432.1 -2452 to 1588 No ns 0.9735
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
DMSO
0 vs. 0.25 17655 18264 -609.4 782.1 6 6 0.7792 60
0 vs. 0.5 17655 17646 8.708 782.1 6 6 0.01113 60
0 vs. 1 17655 5679 11975 782.1 6 6 15.31 60
0 vs. 1.5 17655 3430 14225 782.1 6 6 18.19 60
0 vs. 2 17655 3335 14320 782.1 6 6 18.31 60
ATR-101
0 vs. 0.25 97.19 10721 -10623 782.1 6 6 13.58 60
0 vs. 0.5 97.19 5107 -5010 782.1 6 6 6.405 60
0 vs. 1 97.19 1878 -1781 782.1 6 6 2.277 60
0 vs. 1.5 97.19 324.8 -227.6 782.1 6 6 0.291 60
0 vs. 2 97.19 529.3 -432.1 782.1 6 6 0.5524 60
Table Analyzed S2I. Caspase activity vs. cholesterol:MBCD concentration, 24 h, +ATR-101
Two-way ANOVA Ordinary
Alpha 0.05
2way ANOVA of S2I. Caspase activity vs. cholesterol:MBCD concentration, 24 h, +A
2way ANOVA of S2I. ATP level vs. cholesterol:MBCD concentration, 24 h, +ATR-101
Source of Variation % of total variation P value P value summary Significant?
Interaction 26.56 <0.0001 **** Yes
Row Factor 4.148 <0.0001 **** Yes
Column Factor 65.78 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 3404583799 5 680916760 F (5, 60) = 90.77 P<0.0001
Row Factor 531838324 1 531838324 F (1, 60) = 70.9 P<0.0001
Column Factor 8433825739 5 1686765148 F (5, 60) = 224.9 P<0.0001
Residual 450078122 60 7501302
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 2
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO
0 vs. 0.25 -177.2 -4261 to 3907 No ns 0.9999
0 vs. 0.5 -2720 -6804 to 1364 No ns 0.3016
0 vs. 1 -30563 -34647 to -26479 Yes **** 0.0001
0 vs. 1.5 -30691 -34775 to -26608 Yes **** 0.0001
0 vs. 2 -34079 -38163 to -29995 Yes **** 0.0001
ATR-101
0 vs. 0.25 -11471 -15555 to -7387 Yes **** 0.0001
0 vs. 0.5 -27787 -31871 to -23703 Yes **** 0.0001
0 vs. 1 -26684 -30768 to -22600 Yes **** 0.0001
0 vs. 1.5 -18777 -22860 to -14693 Yes **** 0.0001
0 vs. 2 -19013 -23096 to -14929 Yes **** 0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
DMSO
0 vs. 0.25 926.3 1103 -177.2 1581 6 6 0.1121 60
0 vs. 0.5 926.3 3647 -2720 1581 6 6 1.72 60
0 vs. 1 926.3 31489 -30563 1581 6 6 19.33 60
0 vs. 1.5 926.3 31618 -30691 1581 6 6 19.41 60
0 vs. 2 926.3 35005 -34079 1581 6 6 21.55 60
ATR-101
0 vs. 0.25 5445 16916 -11471 1581 6 6 7.254 60
0 vs. 0.5 5445 33232 -27787 1581 6 6 17.57 60
0 vs. 1 5445 32129 -26684 1581 6 6 16.87 60
0 vs. 1.5 5445 24222 -18777 1581 6 6 11.87 60
0 vs. 2 5445 24458 -19013 1581 6 6 12.02 60
Table Analyzed S4A. Cortisol secretion vs. time, +DMSO or verapamil
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 35.88 <0.0001 **** Yes
Row Factor 37.67 <0.0001 **** Yes
Column Factor 23.09 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 380052 3 126684 F (3, 32) = 113.7 P<0.0001
Row Factor 398945 3 132982 F (3, 32) = 119.4 P<0.0001
Column Factor 244514 1 244514 F (1, 32) = 219.5 P<0.0001
Residual 35645 32 1114
Number of missing values 0
Compare each cell mean with the other cell mean in that row
Number of families 1
Number of comparisons per family 4
Alpha 0.05
Sidak's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
DMSO - verapamil
    0.25 5.998 -49.71 to 61.7 No ns 0.9976
    1 16.38 -39.32 to 72.08 No ns 0.904
    4 117.6 61.92 to 173.3 Yes **** <0.0001
    8 485.5 429.8 to 541.2 Yes **** <0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 t DF
DMSO - verapamil
    0.25 82.15 76.15 5.998 21.11 5 5 0.2842 32
    1 102.7 86.3 16.38 21.11 5 5 0.776 32
    4 198.4 80.75 117.6 21.11 5 5 5.572 32
    8 572 86.53 485.5 21.11 5 5 23 32
Table Analyzed S4B. Cortisol secretion vs. zosuquidar concentration




P value summary ****
Significant diff. among means (P < 0.05)? Yes
R square 0.9246
Brown-Forsythe test
F (DFn, DFd) 0.146 (3, 16)
P value 0.9308
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 1.158
P value 0.7632
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 24991 3 8330 F (3, 16) = 65.36 P<0.0001
Residual (within columns) 2039 16 127.5
Total 27031 19
Data summary
Number of treatments (columns) 4
2way ANOVA of S4A. Cortisol secretion vs. time, +DMSO or verapamil
Ordinary one-way ANOVA of S4B. Cortisol secretion vs. zosuquidar concentration
Number of values (total) 20
Number of families 1
Number of comparisons per family 3
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 5 46.85 28.34 to 65.36 Yes **** 0.0001 B 5
0 vs. 20 85.99 67.48 to 104.5 Yes **** 0.0001 C 20
0 vs. 40 85.77 67.26 to 104.3 Yes **** 0.0001 D 40
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 5 137.3 90.47 46.85 7.14 5 5 6.561 16
0 vs. 20 137.3 51.33 85.99 7.14 5 5 12.04 16
0 vs. 40 137.3 51.55 85.77 7.14 5 5 12.01 16
Table Analyzed S4B. Cortisol secretion vs. ATR-101 concentration, -/+ olesoxime
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 0.3187 0.7403 ns No
Row Factor 0.9476 0.191 ns No
Column Factor 86.17 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 105.9 2 52.97 F (2, 24) = 0.3045 P=0.7403
Row Factor 315 1 315 F (1, 24) = 1.81 P=0.1910
Column Factor 28642 2 14321 F (2, 24) = 82.32 P<0.0001
Residual 4175 24 174
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 2
Number of comparisons per family 2
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101
0 vs. 20 13.46 -6.139 to 33.06 No ns 0.2056
0 vs. 40 75.06 55.46 to 94.66 Yes **** 0.0001
ATR-101+olesoxime
0 vs. 20 14.88 -4.717 to 34.48 No ns 0.1523
0 vs. 40 67.89 48.29 to 87.49 Yes **** 0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
ATR-101
0 vs. 20 126.9 113.5 13.46 8.342 5 5 1.614 24
0 vs. 40 126.9 51.86 75.06 8.342 5 5 8.997 24
ATR-101+olesoxime
0 vs. 20 131.5 116.6 14.88 8.342 5 5 1.784 24
0 vs. 40 131.5 63.59 67.89 8.342 5 5 8.138 24
Table Analyzed S4B. ATP level vs. zosuquidar concentration




2way ANOVA of S4B. Cortisol secretion vs. ATR-101 concentration, -/+ olesoxime
Ordinary one-way ANOVA of S4B. ATP level vs. zosuquidar concentration
P value summary ns
Significant diff. among means (P < 0.05)? No
R square 0.08099
Brown-Forsythe test
F (DFn, DFd) 0.09339 (3, 16)
P value 0.9626
P value summary ns
Are SDs significantly different (P < 0.05)? No
Bartlett's test
Bartlett's statistic (corrected) 0.4373
P value 0.9324
P value summary ns
Are SDs significantly different (P < 0.05)? No
ANOVA table SS DF MS F (DFn, DFd) P value
Treatment (between columns) 1610849 3 536950 F (3, 16) = 0.47 P=0.7074
Residual (within columns) 18279015 16 1142438
Total 19889864 19
Data summary
Number of treatments (columns) 4
Number of values (total) 20
Number of families 1
Number of comparisons per family 3
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P VA-?
0 vs. 5 777.9 -974.7 to 2530 No ns 0.536 B 5
0 vs. 20 463.8 -1289 to 2216 No ns 0.8334 C 20
0 vs. 40 559.5 -1193 to 2312 No ns 0.7478 D 40
Test details Mean 1 Mean 2 Mean Diff. SE of diff. n1 n2 q DF
0 vs. 5 15190 14412 777.9 676 5 5 1.151 16
0 vs. 20 15190 14726 463.8 676 5 5 0.6861 16
0 vs. 40 15190 14630 559.5 676 5 5 0.8276 16
Table Analyzed S4B. ATP level vs. ATR-101 concentration, -/+ olesoxime
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 27.87 <0.0001 **** Yes
Row Factor 17.24 <0.0001 **** Yes
Column Factor 44.53 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 131785155 2 65892577 F (2, 24) = 32.32 P<0.0001
Row Factor 81524118 1 81524118 F (1, 24) = 39.99 P<0.0001
Column Factor 210557403 2 105278702 F (2, 24) = 51.64 P<0.0001
Residual 48925847 24 2038577
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 2
Number of comparisons per family 2
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101
0 vs. 20 350.8 -1771 to 2472 No ns 0.8966
0 vs. 40 10230 8108 to 12352 Yes **** 0.0001
2way ANOVA of S4B. ATP level vs. ATR-101 concentration, -/+ olesoxime
ATR-101+olesoxime
0 vs. 20 463.3 -1658 to 2585 No ns 0.8285
0 vs. 40 1395 -727 to 3516 No ns 0.2311
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
ATR-101
0 vs. 20 16565 16215 350.8 903 5 5 0.3885 24
0 vs. 40 16565 6335 10230 903 5 5 11.33 24
ATR-101+olesoxime
0 vs. 20 16955 16491 463.3 903 5 5 0.513 24
0 vs. 40 16955 15560 1395 903 5 5 1.544 24
Table Analyzed S7A. ABCA1 levels vs. ATR-101 or PD129337 concentration, 4 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 2.73 0.0877 ns No
Row Factor 7.556 <0.0001 **** Yes
Column Factor 76.95 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 0.000001437 5 2.875E-07 F (5, 48) = 2.054 P=0.0877
Row Factor 0.000003978 1 0.000003978 F (1, 48) = 28.42 P<0.0001
Column Factor 0.00004051 5 0.000008102 F (5, 48) = 57.89 P<0.0001
Residual 0.000006718 48 0.00000014
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 2
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101
0 vs. 1 -0.0006868 -0.001302 to -7.141e-005 Yes * 0.0237
0 vs. 5 0.0004594 -0.000156 to 0.001075 No ns 0.2049
0 vs. 10 0.001375 0.00076 to 0.001991 Yes **** 0.0001
0 vs. 20 0.001867 0.001251 to 0.002482 Yes **** 0.0001
0 vs. 40 0.00142 0.0008051 to 0.002036 Yes **** 0.0001
PD129337
0 vs. 1 -0.0006488 -0.001264 to -3.346e-005 Yes * 0.0354
0 vs. 5 0.0006339 1.854e-005 to 0.001249 Yes * 0.0414
0 vs. 10 0.00159 0.0009748 to 0.002206 Yes **** 0.0001
0 vs. 20 0.001402 0.0007868 to 0.002018 Yes **** 0.0001
0 vs. 40 0.0008319 0.0002165 to 0.001447 Yes ** 0.0044
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
ATR-101
0 vs. 1 0.003808 0.004494 -0.0006868 0.0002366 5 5 2.903 48
0 vs. 5 0.003808 0.003348 0.0004594 0.0002366 5 5 1.942 48
0 vs. 10 0.003808 0.002432 0.001375 0.0002366 5 5 5.813 48
0 vs. 20 0.003808 0.001941 0.001867 0.0002366 5 5 7.89 48
0 vs. 40 0.003808 0.002387 0.00142 0.0002366 5 5 6.004 48
PD129337
0 vs. 1 0.004218 0.004867 -0.0006488 0.0002366 5 5 2.742 48
0 vs. 5 0.004218 0.003584 0.0006339 0.0002366 5 5 2.679 48
0 vs. 10 0.004218 0.002628 0.00159 0.0002366 5 5 6.721 48
0 vs. 20 0.004218 0.002816 0.001402 0.0002366 5 5 5.926 48
0 vs. 40 0.004218 0.003386 0.0008319 0.0002366 5 5 3.516 48
Table Analyzed S7A. ABCG1 levels vs. ATR-101 or PD129337 concentration, 4 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 7.819 0.0002 *** Yes
Row Factor 9.738 <0.0001 **** Yes
Column Factor 69.81 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 6.462E-09 5 1.292E-09 F (5, 48) = 5.941 P=0.0002
Row Factor 8.048E-09 1 8.048E-09 F (1, 48) = 37 P<0.0001
2way ANOVA of S7A. ABCG1 levels vs. ATR-101 or PD129337 concentration, 4 h
2way ANOVA of S7A. ABCA1 levels vs. ATR-101 or PD129337 concentration, 4 h
Column Factor 5.77E-08 5 1.154E-08 F (5, 48) = 53.05 P<0.0001
Residual 1.044E-08 48 2.175E-10
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 2
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101
0 vs. 1 -0.00002138 -4.564e-005 to 2.879e-006No ns 0.1008
0 vs. 5 0.00001529 -8.975e-006 to 3.955e-005No ns 0.3479
0 vs. 10 0.00005081 2.655e-005 to 7.507e-005Yes **** 0.0001
0 vs. 20 0.00006651 4.225e-005 to 9.077e-005Yes **** 0.0001
0 vs. 40 0.00006873 4.447e-005 to 9.299e-005Yes **** 0.0001
PD129337
0 vs. 1 -0.00001981 -4.407e-005 to 4.454e-006No ns 0.1436
0 vs. 5 0.000003792 -2.047e-005 to 2.805e-005No ns 0.9932
0 vs. 10 0.0000544 3.014e-005 to 7.866e-005Yes **** 0.0001
0 vs. 20 0.00006837 4.411e-005 to 9.263e-005Yes **** 0.0001
0 vs. 40 0.00001375 -1.051e-005 to 3.801e-005No ns 0.447
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
ATR-101
0 vs. 1 0.0001065 0.0001279 -0.00002138 0.000009328 5 5 2.292 48
0 vs. 5 0.0001065 0.00009125 0.00001529 0.000009328 5 5 1.639 48
0 vs. 10 0.0001065 0.00005572 0.00005081 0.000009328 5 5 5.448 48
0 vs. 20 0.0001065 0.00004003 0.00006651 0.000009328 5 5 7.13 48
0 vs. 40 0.0001065 0.0000378 0.00006873 0.000009328 5 5 7.369 48
PD129337
0 vs. 1 0.0001198 0.0001396 -0.00001981 0.000009328 5 5 2.123 48
0 vs. 5 0.0001198 0.000116 0.000003792 0.000009328 5 5 0.4065 48
0 vs. 10 0.0001198 0.00006539 0.0000544 0.000009328 5 5 5.832 48
0 vs. 20 0.0001198 0.00005142 0.00006837 0.000009328 5 5 7.329 48
0 vs. 40 0.0001198 0.000106 0.00001375 0.000009328 5 5 1.475 48
Table Analyzed S7A. CHOP levels vs. ATR-101 or PD129337 concentration, 4 h
Two-way ANOVA Ordinary
Alpha 0.05
Source of Variation % of total variation P value P value summary Significant?
Interaction 13.09 <0.0001 **** Yes
Row Factor 0.9174 0.0781 ns No
Column Factor 72.41 <0.0001 **** Yes
ANOVA table SS DF MS F (DFn, DFd) P value
Interaction 0.000008642 5 0.000001728 F (5, 48) = 9.25 P<0.0001
Row Factor 6.056E-07 1 6.056E-07 F (1, 48) = 3.241 P=0.0781
Column Factor 0.0000478 5 0.000009559 F (5, 48) = 51.16 P<0.0001
Residual 0.000008969 48 1.868E-07
Number of missing values 0
Within each row, compare columns (simple effects within rows)
Number of families 2
Number of comparisons per family 5
Alpha 0.05
Dunnett's multiple comparisons test Mean Diff. 95.00% CI of diff. Significant? Summary Adjusted P Value
ATR-101
0 vs. 1 -0.0004148 -0.001126 to 0.0002963 No ns 0.4199
2way ANOVA of S7A. CHOP levels vs. ATR-101 or PD129337 concentration, 4 h
0 vs. 5 -0.0004114 -0.001122 to 0.0002997 No ns 0.4277
0 vs. 10 -0.000355 -0.001066 to 0.000356 No ns 0.5661
0 vs. 20 -0.0009965 -0.001708 to -0.0002855 Yes ** 0.003
0 vs. 40 -0.003601 -0.004312 to -0.00289 Yes **** 0.0001
PD129337
0 vs. 1 -0.00005224 -0.0007633 to 0.0006588 No ns 0.9997
0 vs. 5 -0.001126 -0.001837 to -0.0004153 Yes *** 0.0007
0 vs. 10 -0.0004209 -0.001132 to 0.0002901 No ns 0.406
0 vs. 20 -0.000615 -0.001326 to 9.603e-005 No ns 0.1106
0 vs. 40 -0.00182 -0.002531 to -0.001109 Yes **** 0.0001
Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF
ATR-101
0 vs. 1 0.003597 0.004012 -0.0004148 0.0002734 5 5 1.517 48
0 vs. 5 0.003597 0.004008 -0.0004114 0.0002734 5 5 1.505 48
0 vs. 10 0.003597 0.003952 -0.000355 0.0002734 5 5 1.299 48
0 vs. 20 0.003597 0.004593 -0.0009965 0.0002734 5 5 3.645 48
0 vs. 40 0.003597 0.007198 -0.003601 0.0002734 5 5 13.17 48
PD129337
0 vs. 1 0.003687 0.003739 -0.00005224 0.0002734 5 5 0.1911 48
0 vs. 5 0.003687 0.004813 -0.001126 0.0002734 5 5 4.12 48
0 vs. 10 0.003687 0.004108 -0.0004209 0.0002734 5 5 1.54 48
0 vs. 20 0.003687 0.004302 -0.000615 0.0002734 5 5 2.25 48
0 vs. 40 0.003687 0.005507 -0.00182 0.0002734 5 5 6.658 48
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